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2Key points 
• MALT1 protease activity stabilizes MYC
• The MALT1-MYC network might represent a therapeutic target for MCL patients
Abstract 
Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by poor 
clinical outcome. Recent studies revealed the importance of B-cell receptor (BCR) 
signaling in maintaining MCL survival. However, it remains unclear which role 
MALT1, an essential component of the CARD11-BCL10-MALT1 (CBM) complex that 
links BCR signaling to the nuclear factor kappa-B (NF-κB) pathway, plays in the 
biology of MCL. Here we show that a subset of MCLs is addicted to MALT1, as its 
inhibition by either RNA or pharmacologic interference induced cytotoxicity both in 
vitro and in vivo. Gene expression profiling following MALT1 inhibition demonstrated 
that MALT1 controls a MYC-driven gene expression network predominantly through 
increasing MYC protein stability. Thus, our analyses identify a previously 
unappreciated regulatory mechanism of MYC expression. Investigating primary 
mouse splenocytes, we could demonstrate that MALT1-induced MYC regulation is 
not restricted to MCL, but represents a common mechanism. MYC itself is pivotal for 
MCL survival as its downregulation and pharmacologic inhibition induced cytotoxicity 
in all MCL models. Collectively, these results provide a strong mechanistic rationale 
to investigate the therapeutic efficacy of targeting the MALT1-MYC axis in MCL 
patients.  
3Introduction 
Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and 
short overall survival.1 Different cytomorphological variants can be distinguished and 
especially, blastic variants are associated with poor overall survival.2-4 Besides 
clinical factors summarized in the mantle cell lymphoma international prognostic 
index (MIPI), high cell proliferation has been identified as a major prognostic factor 
associated with adverse outcome.5-7  
Pathogenetically MCL is characterized by cyclin D1 overexpression due to the 
chromosomal translocation t(11;14)(q13;q32).8 In addition, various secondary genetic 
aberrations activating different pathways have been elucidated.9,10 Recently, 
constitutive activation of B-cell receptor (BCR) signaling and downstream activation 
of the nuclear factor kappa-B (NF-κB) pathway have been identified to be critical for 
survival of MCL subsets.11,12 Upon BCR stimulation MALT1 and BCL10 are recruited 
to CARD11 resulting in the formation of the CARD11-BCL10-MALT1 (CBM) complex 
and NF-κB activation.13,14 Additionally, the protease activity of MALT1 is enhanced 
leading to cleavage of NF-κB inhibitors such as A20 and RelB.15,16 Other known 
MALT1 substrates include BCL10, CYLD, Regnase-1, Roquin-1, Roquin-2, and 
HOIL1.17-25  
Preliminary data suggested that MALT1 is constitutively activated in subsets of 
MCL.11 However, its precise role in the pathogenesis of MCL remains unknown. 
Thus, we investigated the role of MALT1 in the biology of MCL in the current study. 
4Methods 
Patient samples, immunohistochemistry and fluorescence in situ hybridization 
(FISH)  
CD20+ MCL cells were separated from peripheral blood mononuclear cells (PBMCs; 
patient samples #1 and #2) or cell suspensions from lymph nodes (patient samples 
#3-5) of MCL patients by CD20 magnetic-activated cell sorting (Miltenyi Biotec, 
Bergisch Gladbach, Germany).  
The immunohistochemical protocols are summarized in the Supplemental 
Material and Methods. FISH was performed as described.26,27  
Cell culture, retroviral constructs and transductions 
The experiments were performed as described.28-30 Protocols are available in the 
Supplemental Material and Methods. The sequences of the utilized small hairpin 
RNAs (shRNAs) are summarized in Supplemental Table 1. 
Viability assay, analysis of cell cycle, apoptosis and proliferation 
The experiments were performed as described.29,31,32 Protocols are available in the 
Supplemental Material and Methods. 
Isolation and stimulation of mouse splenocytes 
Protocols are available in the Supplemental Material and Methods. 
In vivo xenograft mouse studies 
The in vivo xenograft mouse studies were done as described.33 Protocols are 
available in the Supplemental Material and Methods.  
5Gene expression profiling 
Gene expression profiling was performed 24, 30, 36, 42, 48, and 54 hours following 
treatment with z-VRPR-fmk or DMSO in Mino and Rec-1 cells and analyzed as 
described in Supplemental Material and Methods.32,34,35 The gene expression data 
has been deposited in the GEO database (http://www.ncbi.nlm.nih.gov/geo; 
accession number GSE81552). 
Quantitative PCR 
Quantitative PCR was performed as described using predesigned assays (Applied 
Biosystems, Carlsbad, CA, USA).29  
Western blotting and analysis of MYC stability 
Protocols are available in the Supplemental Material and Methods. 
Results 
MALT1 is expressed and activated in MCL 
To assess if MALT1 is expressed in MCL, we determined its expression in 60 primary 
samples by immunohistochemistry. To establish the immunohistochemical assay, we 
stained five reactive lymph node and tonsil specimens. MALT1 was expressed in 
both B- and T-cell areas of the lymph node, albeit to varying degrees. The germinal 
center (GC) B-cells were strongly positive and staining was accentuated in the dark 
zone of the GC (Supplemental Figure 1). 56/60 (93%) of MCL cases stained positive 
for MALT1 and showed a diffuse cytoplasmic expression that was detectable in 
virtually all MCL cells (Figure 1A-B). We compared this expression pattern to other 
aggressive lymphomas by staining 81 primary DLBCL samples. We determined the 
6molecular DLBCL subtype by applying the Hans algorithm36 and identified 34 GCB 
and 47 non-GCB DLBCLs. All 34 GCB as well as 46 out of the 47 (98%) non-GCB 
DLBCLs expressed MALT1 suggesting that different B-cell lymphoma subtypes 
express MALT1. 
MALT1 functions as a protease and therefore its proteolytic activity is 
determining its biologic function. Thus, to determine MALT1 activity in primary MCL 
samples, we prepared cell lysates from CD20+ MCL cells that were isolated from 
either PBMCs or cell suspensions from affected lymph nodes. MALT1 expression 
was found in all five primary MCL samples, whereas CYLD cleavage as a direct 
marker of MALT1 proteolytic activity22 was detectable in four out of five samples 
(Figure 1C).  
To investigate MALT1 activity in additional MCLs, we analyzed ten established 
cell lines. MALT1 was expressed in all lines assessed by Western blotting (Figure 
1D). Five cell lines (Mino, Jeko-1, Rec-1, SP49, and SP53) had detectable levels of 
cleaved forms of CYLD, RelB, A20, and BCL10 indicating constitutive MALT1 activity. 
In contrast, the other cell lines did not show cleavage of MALT1 targets suggesting 
absent MALT1 proteolytic activity (Figure 1E). Collectively, these data implicate that 
MALT1 is constitutively active in a substantial number of MCLs and that MCLs can be 
divided into two distinct subgroups based on their MALT1 activation status.  
Activation of MALT1 in MCL is caused by constitutive BCR signaling 
Next, we investigated the mechanisms leading to MALT1 activation in MCL. As BCR 
signaling is an activator of MALT1, we knocked down CD79A and CARD11 as central 
components of the BCR cascade to investigate the effects on MALT1 activity. 
Cleavage of the MALT1 targets CYLD, RelB, and BCL10 was significantly decreased 
in two MALT1-activated cell lines (Jeko-1 and Rec-1), but unaffected in two MALT1-
7inactive MCL cell lines (Maver-1 and Z-138) after CD79A and CARD11 knockdown 
using specific shRNAs, respectively (Figure 2A). These results suggest that MALT1 
is activated through constitutive BCR signaling in MCL. Interestingly, shRNA-
mediated knockdown of CD79A, CARD11 or the CBM complex component BCL10 
induced toxicity in Jeko-1 and Rec-1 cells, but not in Maver-1 and Z-138 cells, 
indicating dependency on BCR signaling only in MALT1-activated MCLs (Figure 2B 
and Supplemental Figure 2A-B). These results were further confirmed by 
experiments showing that all MALT1-activated MCL cell lines were sensitive to the 
Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, whereas all MALT1-inactive models 
did not respond (Figure 2C). 
Downregulation of MALT1 is toxic to MALT1-activated MCLs in vitro and in vivo 
To elucidate the functional significance of MALT1 in MCL, we knocked down its 
expression using different MALT1-specific shRNAs. Both shRNAs significantly 
decreased MALT1 mRNA and protein levels after 48 hours (Figure 3A-B). 
Transduction of MALT1 shRNAs induced cytotoxicity in MALT1-activated MCLs while 
it did not affect survival of any of the MALT1-inactive models (Figure 3C). To 
demonstrate that MALT1 shRNA-mediated toxicity was specifically caused by MALT1 
knockdown, we performed a rescue experiment by transducing Jeko-1 and Rec-1 
cells with a vector carrying the MALT1 cDNA that is not targetable by both MALT1 
shRNAs. Indeed, exogenous MALT1 expression restored growth of both MALT1-
activated MCL models, indicating the specificity of our approach (Figure 3D). 
We next determined if MALT1 dependency in MALT1-activated MCLs 
translates into an in vivo setting. To this end, we created MCL xenograft mouse 
models using Jeko-1 cells transduced with vectors encoding either MALT1 shRNA #2 
or a negative control shRNA. shRNA-mediated MALT1 knockdown was detectable by 
8Western blotting in different samples from sacrificed mice (Figure 3E). MALT1 
knockdown significantly inhibited tumor growth over 12 days (P = 1.9×10−5 for MALT1 
shRNA vs. control shRNA on day 12; one-tailed two-sample t-test; Figure 3F), 
suggesting that MALT1 promotes lymphoma growth in MALT1-activated MCLs.  
Next, we asked if signaling through MALT1 can be utilized therapeutically in 
MCL. Thus, we treated our MCL lines with the specific MALT1 inhibitor z-VRPR-
fmk.23 To confirm that z-VRPR-fmk indeed exerts its effect through inhibiting 
MALT1´s proteolytic activity, expression of the MALT1 targets CYLD, RelB, A20, and 
BCL10 were studied 48 hours after incubation with z-VRPR-fmk by immunoblotting. 
We detected a significant downregulation of their cleaved forms in MALT1-activated 
MCLs (Mino and SP53). In contrast, no changes in their expression levels were 
observed in the MALT1-inactive MCLs (Maver-1 and Z-138) (Figure 3G). These 
results confirm that z-VRPR-fmk inhibits the proteolytic function of MALT1. 
Subsequently, we determined cell viability seven days after z-VRPR-fmk treatment. 
In line with our MALT1 knockdown data, pharmacologic inhibition of MALT1 
significantly reduced cell viability of MALT1-activated MCLs, whereas survival of 
MALT1-inactive MCLs was not affected (Figure 3H).  
To obtain insights into the nature of the growth inhibitory effects of MALT1 
inhibition through z-VRPR-fmk, we measured cell proliferation, the rate of apoptosis, 
and performed cell cycle analyses. We treated MALT1-activated (Mino) and MALT1-
inactive (Z-138) MCLs with z-VRPR-fmk or DMSO. To assess proliferation, cellular 
divisions were determined by measuring CFSE dilutions in viable cells by flow 
cytometry. z-VRPR-fmk significantly downregulated proliferation of Mino cells (P < 
10−15 on day 6) , while Z-138 cells were not affected (P = .4 on day 6; Figure 3I). In 
addition, we quantified the number of cell divisions following treatment with z-VRPR-
fmk. These analyses revealed that Mino cells divided 1.8 ± 0.17 or 0.9 ± 0.1 ×/d after 
9DMSO or z-VRPR-fmk treatment, respectively, whereas Z-138 cells divided 2.6 ± 
0.03 x/d after DMSO treatment and 2.5 ± 0.04 ×/d following MALT1 inhibition. In 
contrast, neither changes in apoptosis (data not shown) nor cell cycle (Supplemental 
Figure 3) were detectable following MALT1 inhibition, indicating that z-VRPR-fmk 
exerts its growth inhibitory effect in MALT1-activated MCLs predominantly through 
reduction of cell proliferation (Figure 3I). 
Inhibition of MALT1 overcomes ibrutinib resistance 
The BTK inhibitor ibrutinib is effective in the treatment of relapsed/refractory MCL 
patients.37 A recent study identified that the BTKC481S mutation confers resistance to 
ibrutinib in MCL.38 To investigate whether inhibition of MALT1 is able to overcome 
BTKC481S-induced ibrutinib resistance, we expressed a BTKC481S cDNA or an empty 
vector in all five MALT1-activated and two MALT1-inactive MCL lines (Figure 3J and 
Supplemental Figure 4A,C,E,G,I,K) and subsequently treated these cells with 
ibrutinib or z-VRPR-fmk. Introduction of the BTKC481S mutation rescued all MALT1-
activated lines from the toxic effect of ibrutinib (Figure 3K and Supplemental Figure 
4B,D,F,H). In contrast, in MALT1-inactive MCLs transduction of the BTKC481S mutant 
or an empty vector did not alter sensitivity to ibrutinib or z-VRPR-fmk (Figure 2C and 
3H; Supplemental Figure 4J,L). These data indicate that inhibition of MALT1 might be 
effective in ibrutinib resistant MCLs. 
MALT1 regulates MYC expression in MCL 
To understand which biologic processes are regulated by MALT1 in MCL, we profiled 
gene expression changes after 24, 30, 36, 42, 48, and 54 hours of z-VRPR-fmk 
treatment in Mino cells. We identified 93 genes that were significantly downregulated 
(P ≤ 1×10−5; paired t-tests over all time points) and 126 genes significantly 
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upregulated (P ≤ 1×10−5) following pharmacologic MALT1 inhibition (Figure 4A; 
Supplemental Figure 5A; Supplemental Table 2). 
To analyze the gene expression data in an unbiased manner, we performed a 
gene set enrichment analysis using a previously described gene expression 
signatures database consisting of 13,593 signatures (Supplemental Table 3). Our 
analysis revealed that the second most enriched downregulated signature was a 
previously described MYC target gene set (enrichment score = 0.841; P ≤ .001; 
Figure 4B; Supplemental Figure 5B; Supplemental Table 3). In addition, various other 
independent MYC signatures were significantly enriched with downregulated genes 
and among the top downregulated signatures, suggesting that MYC expression and 
its gene expression network is regulated by MALT1 (Supplemental Table 3-4). 
To confirm that MYC deregulation by MALT1 is a general mechanism in MCL, 
we further performed gene expression profiling in Rec-1 cells (Supplemental Figure 6 
A-B; Supplemental Table 5). These analyses confirmed that various previously 
identified MYC target sets were downregulated following z-VRPR-fmk treatment 
(Supplemental Figure 6C-D; Supplemental Table 6-7). Additionally, the identified 
Mino target gene signature was significantly downregulated in Rec-1 following 
MALT1 inhibition (Supplemental Figure 6E) suggesting that very similar target genes 
are affected by MALT1 inhibition in Mino and Rec-1 cells. Finally, to confirm that the 
detected Mino target gene signature is also downregulated in other MCL models, we 
performed real-time PCR for eleven selected genes following MALT1 inhibition in 
both MALT1-activated and MALT1-inactive cell lines. Real-time PCR confirmed 
downregulation of ten out of eleven target genes in all MALT1-activated but not 
MALT-inactive models (Figure 4C and Supplemental Figure 7). These results 
suggest that the MYC target gene network seems to be controlled by MALT1 in 
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MCL. In contrast, previously identified NF-κB target gene signatures were not 
affected by MALT1 inhibition in both Mino and Rec-1 cells. 
Due to the strong impact of MALT1 inhibition on the MYC expression profile, 
we asked whether MYC itself is regulated by MALT1. MYC mRNA expression was 
moderately suppressed by MALT1 inhibition (log2(ratio) = −.33 in Mino and log2(ratio) 
= −.23 in Rec-1). This result was confirmed by shRNA-mediated MALT1 knockdown 
that did not substantially alter MYC mRNA levels measured by quantitative PCR 
(Figure 4D). To elucidate if MYC is regulated posttranscriptionally by MALT1, we 
evaluated MYC protein expression after z-VRPR-fmk treatment. Immunoblotting 
revealed that MYC levels were reduced in MALT1-activated but not in MALT1-
inactive MCLs following MALT1 inhibition (Figure 4E). 
To corroborate these findings, we next investigated MYC expression levels 
following shRNA-mediated MALT1 knockdown in MALT1-activated and -inactive cells 
by Western blotting. MALT1 silencing induced a substantial decrease in MYC protein 
levels in MALT1-activated but not MALT1-inactive MCLs (Figure 4F). As MALT1 is 
activated by BCR signaling in MCL, we investigated whether inhibition of BCR 
signaling by ibrutinib alters MYC expression levels. To this end we treated MALT1-
activated (Mino and Rec-1) and MALT1-inactive (Maver-1 and Z-138) cell lines with 5 
and 10 nM ibrutinib for 12, 24, 36, and 48 hours. Ibrutinib treatment significantly 
decreased MYC expression in Mino and Rec-1 cells, whereas MYC levels in Maver-1 
and Z-138 were unaffected (Supplemental Figure 8). Collectively, these data indicate 
that BCR-driven MALT1 activity regulates MYC expression.  
MALT1 regulates MYC expression in primary mouse splenocytes 
To elucidate if MALT1-induced regulation of MYC protein expression is relevant in 
other settings than MCL, we isolated primary mouse splenocytes expressing either 
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wild-type MALT1 (+/+) or a catalytically inactive MALT1C472A mutant (ki/ki)39 and 
subsequently stimulated the splenocytes with PMA and ionomycin for 30, 60, and 
120 minutes (Figure 5A). Stimulation of MALT1 (+/+) and MALT1 (ki/ki) splenocytes 
was equally strong, as determined by monitoring the induction of ERK 
phosphorylation (Figure 5A). In contrast, CYLD cleavage, which served as a marker 
of MALT1 activity, was only detectable in MALT1 (+/+) splenocytes. Likewise, the 
stimulation-induced expression of MYC was considerably stronger in MALT1 (+/+) 
compared to MALT1 (ki/ki) splenocytes. Collectively, these findings suggest that 
MALT1 activity promotes MYC expression in activated primary lymphocytes (Figure 
5A). 
MALT1 stabilizes MYC expression 
Next, we investigated whether MALT1 promotes MYC expression by controlling MYC 
protein stability. We treated Rec-1 and Mino cells with 50 μM z-VRPR-fmk or DMSO 
for 24 hours, followed by incubation with 10 μg/mL of the protein synthesis inhibitor 
cycloheximide. Immunoblotting revealed that MYC levels in Rec-1 cells declined 
faster following z-VRPR-fmk treatment (half-life 31.5 minutes) compared to DMSO 
(69.31 minutes). This was confirmed in Mino cells, in which the half-life of MYC 
decreased from 46.21 minutes in DMSO treated cells compared to 34.65 minutes in 
MALT1-inhibited cells (Figure 5B and Supplemental Figure 9A). 
Next, to decipher if MALT1 affected proteasomal degradation of MYC, we 
assessed MYC levels in Mino, Rec-1, and SP53 cells that were incubated with z-
VRPR-fmk or DMSO for 12 hours and 24 hours, respectively, followed by treatment 
with the proteasome inhibitor MG132 for two hours. Under these conditions, we 
detected a marked increase of MYC expression in z-VRPR-fmk and MG132 treated 
cells (Figure 5C and Supplemental Figure 9B). To confirm our MALT1 inhibitor data, 
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we transduced MALT1-activated (Rec-1 and SP53) and MALT1-inactive (Maver-1 
and Z-138) MCLs with our two MALT1 shRNAs and treated these cells with either 
DMSO or MG132. MG132 treatment significantly increased MYC expression levels 
following shRNA-mediated MALT1 knockdown in MALT1-activated MCLs (Figure 
5D). Collectively, these results indicate that MALT1 increases MYC stability 
posttranslationally by preventing its proteasomal degradation. 
MCLs depend on MYC signaling 
Our analyses implicated that MALT1 regulates MYC expression. To validate these 
findings, we determined MYC expression in our cell lines and in MCL patient 
samples. All MCL cell lines expressed MYC protein by Western blotting irrespective 
of their MALT1 activation status (Figure 6A and Supplemental Figure 10), whereas 
the four MALT1-activated primary MCLs showed higher MYC expression levels 
compared to the MALT1-inactive specimen (Figure 1C). 
Next, we determined MYC expression in 234 primary MCL samples. 104 
(44.4%) samples did not show MYC expression. In contrast, 75 (32.1%) samples 
displayed an intermediate and 55 (23.5%) samples a high MYC positivity (Figure 6B-
C). To compare the MYC staining pattern in MCL to other lymphomas, we stained 93 
primary DLBCLs (10 MYC rearranged) and 7 BLs (all MYC rearranged). In BLs 
nuclear positivity was strong in >90% of cells. Eight out of ten MYC rearranged 
DLBCLs expressed MYC, while 52 out of 83 primary non-rearranged DLBCLs were 
MYC positive. In general, primary DLBCLs and MCLs were similar with respect to 
their staining intensity and more variable compared to the BL cases (Supplemental 
Figure 11). 
To investigate if MYC expression correlates with the cytological subtype, we 
compared MYC expression in classical (n = 154), pleomorphic (n = 34), and blastoid 
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(n = 40) MCLs (Figure 6D). For six samples the cytological subtype was not 
available. MYC expression was significantly higher in pleomorphic (P = 9.9×10−4) and 
blastoid variants (P = 2.6×10−5) compared to classical MCLs. There was no 
difference in MYC expression between pleomorphic and blastoid MCLs (P = .4; 
Figure 6D).  
To rule out that genetic aberrations involving the MYC locus are causative for 
increased MYC expression, we performed FISH in 80 MCLs with available MYC 
expression data. 55 (69%) of these cases were classical, 6 (8%) pleomorphic, and 13 
(16%) blastoid MCLs (for six cases the cytological subtype was not available). 40 
(50%) cases did not express MYC, 28 (35%) had intermediate MYC expression, 
whereas 12 (15%) samples had high MYC expression. Of the 80 cases, only one 
(1.3%) harbored a MYC translocation, whereas none of the cases showed a high-
level MYC amplification, indicating that these genetic aberrations are extremely rare 
in MCL. 
To elucidate the functional role of MYC expression in MCL, we transduced 
MCL cell lines with specific MYC shRNAs, which induced MYC downregulation 48 
hours after induction (Supplemental Figure 12A). MYC knockdown was lethal to all 
MCL models (Figure 7A). To confirm the specificity of our approach, an exogenous 
MYC cDNA (which is not targeted by MYC shRNA #2) was introduced in Jeko-1, 
Rec-1, and SP53 cells prior to transduction with the MYC shRNA. Indeed, exogenous 
MYC expression rescued all MCL cells from shRNA-mediated toxicity (Figure 7B).  
To evaluate the degree to which MYC downregulation contributes to the 
impaired viability of MALT1-silenced cells, we performed a rescue experiment 
introducing a MYC cDNA or an empty vector into MALT1 shRNA-transduced Jeko-1, 
Rec-1, and SP53 cells. We detected a partial MYC-induced rescue in all three cell 
lines suggesting that MYC knockdown, at least partially, contributes to the lethal 
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effect of MALT1 silencing in these cells (Figure 7C; Supplemental Figure 12B). To 
confirm these results, we treated Jeko-1, Rec-1, SP53, and Mino cells that expressed 
either MYC cDNA or an empty vector with z-VRPR-fmk. In all cell lines we could 
detect a substantial MYC-induced rescue confirming that MYC downregulation is at 
least partially causative for the toxic effects of MALT1 inhibition in MALT1-activated 
MCLs (Figure 7D). To investigate whether this rescue effect is specific to z-VRPR-
fmk, we determined cell viability of these exogenous MYC harboring cells after 
doxorubicin treatment. No resistance against doxorubicin was conferred by MYC 
cDNA expression, indicating the specificity of our findings (Supplemental Figure 
12C). 
To obtain insights into the nature of the growth inhibitory effects of MYC 
knockdown, we analyzed whether cell proliferation was negatively affected by MYC 
silencing. To this end, SNARF-1 staining was performed in Rec-1 and SP53 cells 
expressing MYC shRNA #1/#2. Cell divisions were compared after two days between 
cells with and without MYC knockdown. In both cell lines, the proliferation rate 
decreased substantially after MYC silencing (Figure 7E) indicating that MYC controls 
MCL proliferation.  
To validate our in vitro findings, we stained our cohort of primary MCL samples 
for Ki-67 to assess proliferation. Indeed, overall Ki-67 and MYC expression correlated 
(r = .63; P = 5×10−27; Supplemental Figure 12D). Furthermore, samples with 
intermediate MYC expression had higher Ki-67 levels compared to MYC negative 
MCLs (P = 1.1×10−6; Figure 7F) whereas MYC positive MCLs had the highest Ki-67 
levels (P = 4.6×10−24 vs. MYC negative MCLs and P = 1.4×10−12 vs. MYC 
intermediate MCLs; Figure 7F). This suggests that MYC regulates MCL proliferation 
in vivo. 
16
Finally, we investigated if inhibiting MYC signaling can be exploited 
therapeutically. Cell viability was measured three days after treating MCL lines with 
the small molecule inhibitor 10058-F4 that inhibits MYC-MAX heterodimerization. 
U266 cells that do not express MYC were used as a negative control. Irrespective of 
MALT1 activity, three cell lines (Mino, Rec-1, and Z-138) were highly sensitive to 
10058-F4. In contrast, U266 cells were virtually unaffected, whereas Maver-1 cells 
showed an intermediate sensitivity (Figure 7G). Taken together, these data suggest 
that MYC represents a promising target for future therapies of MCL patients. 
Discussion 
We detected a novel role of MALT1 in the biology of MCL. A substantial fraction of 
MCLs exhibit constitutive MALT1 activity and these MCLs are addicted to MALT1 
function. In contrast, some MCLs do not show constitutive MALT1 proteolytic activity 
and these lymphomas do not depend on MALT1. Thus, our results indicate that 
MCLs can be divided into two distinct subgroups based on their MALT1 activation 
status. 
MALT1 activity seems to be caused by constitutive BCR signaling. Recent 
work showed that activity of BCR signaling is correlated with increased MCL 
proliferation.12 It seems conceivable that this could be caused by MALT1-induced 
upregulation of the oncogenic transcription factor MYC. MYC is crucial for the 
regulation of cell proliferation.40 In line, pharmacologic MALT1 inhibition or shRNA-
mediated MYC knockdown significantly decreased MCL proliferation. Moreover, Ki-
67 expression as a marker for cell proliferation was significantly higher in primary 
MCL samples with MYC expression. MYC expression was detectable in more than 
55% of primary MCLs indicating that MYC is frequently expressed in MCL. In our 
series of primary samples common genetic aberrations such as MYC locus 
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translocations or high-level amplifications that can cause upregulation of MYC were 
extremely rare, confirming results of previous studies.41,42 However, given that MYC 
expression and MALT1 activation status did not correlate in all cell lines, additional 
molecular mechanisms regulate MYC expression in MCL besides MALT1 activity.  
Recent work in chronic lymphocytic leukemia (CLL) has linked BCR signaling 
to upregulation of MYC expression, as anti-IgM-induced BCR signaling increased 
translation of MYC mRNA in primary CLL cells.43 However, the exact molecular 
mechanisms how BCR signaling and MYC expression are linked were not elucidated. 
Our data using primary splenocytes suggest that MALT1-driven MYC expression is 
not restricted to MCL, but seems to be a common mechanism of MYC regulation. 
MALT1 seems to regulate MYC expression through different mechanisms. We 
detected a very moderate MYC downregulation on mRNA level following MALT1 
knockdown or pharmacologic inhibition of MALT1. However, the predominant 
mechanism of MYC regulation involves control of MYC stability. 
Interestingly, our gene expression data following MALT1 inhibition failed to 
show downregulation of previously identified NF-κB gene sets including signatures 
defined in MCL.12 This finding is surprising given the role of MALT1 in activating NF-
κB signaling. The protease activity of MALT1 is dispensable for initial NF-κB 
activation and instead promotes NF-κB signaling through cleavage of the negative 
NF-κB regulators RelB and A20.15,16,44 The mechanisms why downregulation of NF-
κB was not detectable by our transcriptome analyses are unclear and should be 
addressed in future studies. 
Finally, our work revealed that the MALT1-MYC network could be exploited 
therapeutically in MCL patients. Despite improvements in therapy, MCL remains an 
incurable disease.1 MALT1 inhibition was highly effective in all MALT1-activated 
models. These data warrant future clinical trials with MALT1 inhibitors in MCL 
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patients with constitutive MALT1 activity. Moreover, MALT1 inhibition was able to 
overcome BTKC481S-induced ibrutinib resistance and might represent a novel 
therapeutic option for patients failing ibrutinib therapy. Similarly, MYC inhibition was 
lethal to MYC expressing models. These data suggest that MYC inhibition offers a 
promising target and a novel therapeutic strategy to overcome therapy resistance in 
MCL patients. 
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Figure Legends 
Figure 1. MALT1 expression and activity in MCL. (A) Immunohistochemical 
MALT1 staining of a MALT1 positive MCL case (left picture; original magnification 
×200) and a MALT1 negative MCL case (right picture; original magnification ×100).
Images were captured using a Leitz DMRB microscope (Leica Microsystems, Wetzlar, 
Germany) equipped with Fluotar objective lenses (10×/0.30 NA, 20×/0.50 NA) and a 
KY-F75U digital camera (Victor, Yokohama, Japan) and were processed with the 
Diskus Program 4.20 (Hilgers Technical, Königswinter, Germany) that converts and 
exports images in jpeg file format. (B) MALT1 expression in MCLs determined by 
immunohistochemistry. (C) Western blot analysis of MALT1, full-length and cleaved 
forms of CYLD and MYC. MALT1 was highly expressed in CD20+ cells isolated from 
either PBMCs (patient samples #1 and #2) or lymph nodes (patient samples #3, #4, 
and #5) of five primary MCL patient samples. Cleaved CYLD indicating MALT1 
proteolytic activity was detectable in four of five patient samples. MYC expression 
was higher in these four samples with activated MALT1. The MCL cell line Z-138 was 
used as a positive control for MALT1 expression and as a negative control for CYLD 
cleavage. Asterisk indicates non-specific band, which was not observed in any 
MALT1-activated MCL cell lines (Figure 1E). (D) Western blot analysis of MALT1 
expression in MCL cell lines. MALT1 protein expression was detectable in all MCL 
cell lines. (E) Western blot analysis of different MALT1 targets. Cleaved forms of 
CYLD, RelB, A20, and BCL10 were detectable in Mino, Jeko-1, Rec-1, SP49, and 
SP53 cells. Asterisk indicates non-specific band. 
Figure 2. Activation of MALT1 is caused by constitutive BCR signaling in MCL. 
(A) Western blot analysis of CD79A, CARD11, CYLD, RelB, and BCL10 following 
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shRNA-mediated knockdown of CD79A and CARD11, respectively. Cleavage of 
CYLD, RelB, and BCL10 was significantly downregulated following CD79A or 
CARD11 knockdown, respectively, in MALT1-activated cell lines (Jeko-1 and Rec-1), 
whereas none of these cleaved forms was detectable in MALT1-inactive cell lines 
(Maver-1 and Z-138) and the expression levels of the corresponding full-length forms 
were not affected. (B) shRNA-mediated knockdown of CD79A and CARD11 was 
toxic to the MALT1-activated cell lines Jeko-1 and Rec-1. In contrast, the MALT1-
inactive cell lines Maver-1 and Z-138 were unaffected by CD79A and CARD11 
knockdown. A previously described non-toxic shRNA against MSMO1 did not induce 
toxicity in any cell line. Data are shown as means ± standard deviation of at least 
three independent experiments. (C) Cell viability of MCL cell lines after incubation 
with the BTK inhibitor ibrutinib. Representative results from at least three 
independent replicates are shown. Error bars indicate the standard deviation. 
Figure 3. Subsets of MCLs are addicted to MALT1. (A) Effect of MALT1 shRNA #1 
and #2 on MALT1 mRNA level in MALT1-activated (Jeko-1 and Rec-1) and MALT1-
inactive (Maver-1 and Z-138) MCLs 48 hours after shRNA induction measured by 
quantitative PCR. MALT1 mRNA levels were normalized to expression of GAPDH. 
Error bars indicate the standard deviation. (B) Effect of MALT1 shRNA #1 and #2 on 
MALT1 protein in MALT1-activated (Jeko-1 and Rec-1) and MALT1-inactive (Maver-1 
and Z-138) MCLs 48 hours after shRNA induction measured by Western blotting. (C) 
Effect of MALT1 knockdown by two independent shRNAs on viability of MCL cell 
lines. A previously described non-toxic shRNA against MSMO1 did not induce toxicity 
in any cell line. Data are shown as means ± standard deviation of at least three 
independent experiments. (D) Rescue of Jeko-1 and Rec-1 cells from MALT1 
shRNA-induced toxicity by exogenous expression of a MALT1 cDNA. Data are 
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shown as means ± standard deviation of at least three independent experiments. (E) 
Western blot analysis of MALT1 knockdown in Jeko-1 mouse xenograft tumor 
biopsies from cells transduced with MALT1 shRNA #2 compared to control shRNA 
transduced cells (shRNA against MSMO1). (F) Tumor growth curve of Jeko-1 
xenograft mouse models that inducibly express MALT1 shRNA #2 (blue) or a control 
shRNA against MSMO1 (red). MALT1 knockdown significantly reduced in vivo tumor 
growth (P = 1.9×10−5, MALT1 shRNA vs. control shRNA on day 12; one-tailed two-
sample t-test). Error bars indicate the standard deviation. (G) Western blot analysis of 
MCL cell lines, treated with z-VRPR-fmk for 48 hours, for cleavage of CYLD, RelB, 
A20, and BCL10 in MALT1-activated MCL cell lines (Mino and SP53) vs. MALT1-
inactive MCLs (Maver-1 and Z-138). (H) Cell viability of MCL cell lines after 
incubation with the MALT1 inhibitor z-VRPR-fmk. Representative results from at least 
three independent replicates are shown. Error bars indicate the standard deviation. 
(I) CFSE staining after treatment with z-VRPR-fmk or DMSO was measured on day 
zero and after two, four, and six days. In Z-138 cells, no difference in cell proliferation 
was detectable (P = .4 on day 6). In contrast, Mino cells showed reduced proliferation 
after treatment with z-VRPR-fmk (P < 10−15 on day 6). Representative results from at 
least three independent replicates are shown. (J) Western blotting for FLAG and BTK 
following transduction of Mino cells with either a BTKC481S cDNA or an empty vector. 
(K) Determination of cell viability of Mino cells expressing either an empty vector (red) 
or a BTKC481S cDNA (blue) following treatment with ibrutinib or z-VRPR-fmk. 
Representative results from at least three independent replicates are shown. Error 
bars indicate the standard deviation. 
* P < .05, ** P < .01, *** P < .001.
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Figure 4. MALT1 regulates the gene expression network of MYC in MCL. (A) 
Gene expression profiling following pharmacologic inhibition of the proteolytic MALT1 
activity using z-VRPR-fmk vs. DMSO in Mino cells. Changes of gene expression 
were profiled at the indicated time points following treatment with z-VRPR-fmk. Each 
time point depicted the mean of log2-transformed expression ratios for two replicates. 
Gene expression changes were depicted according to the color scale shown. Genes 
that are involved in critical biological processes are highlighted. (B) Gene set 
enrichment analysis of a previously described MYC gene expression signature. The 
MYC signature was significantly enriched with genes that are downregulated 
following pharmacologic MALT1 inhibition using z-VRPR-fmk in Mino cells. (C) 
Expression levels of MALT1 target genes in MALT1-activated and -inactive MCL cell 
lines determined by quantitative PCR. mRNA levels of PFKM, CARD9, and MLKL 
were normalized to expression of GAPDH. Error bars indicate the standard deviation. 
(D) MYC mRNA levels in Rec-1 and SP53 cells following shRNA-mediated 
knockdown of MALT1 as measured by quantitative PCR. MYC mRNA levels were 
normalized to expression of GAPDH. Error bars indicate the standard deviation. (E) 
Treatment with z-VRPR-fmk downregulated MYC protein in the MALT1-activated 
MCL cell lines Mino and Rec-1. In contrast, in the MALT1-inactive cell lines Maver-1 
and Z-138 MYC was not affected by inhibition of MALT1 activity. Accumulation of full-
length BCL10 in MALT1-activated MCL models after treatment with z-VRPR-fmk was 
used as a surrogate marker of MALT1 inhibition. (F) MALT1 shRNA #1 and #2 
downregulated MYC protein in MALT1-activated MCLs (Rec-1 and SP53), but not in 
MALT1-inactive MCLs (Maver-1 and Z-138) at the indicated time points after shRNA 
induction as measured by Western blotting.
N.D., not detectable, N.S., not significant, * P < .05, ** P < .01, *** P < .001. 
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Figure 5. MYC is stabilized by MALT1 function. (A) Primary mouse splenocytes 
expressing either wild-type MALT1 (+/+) or a catalytically inactive MALT1 mutant 
(ki/ki) were stimulated with PMA and ionomycin for the indicated time points. 
Stimulation efficiency and MALT1 activation were assessed by Western blotting using 
anti-p-ERK and anti-CYLD antibodies, respectively. (B) Rec-1 and Mino cells were 
first treated with z-VRPR-fmk or DMSO for 24 hours and subsequently with 
cycloheximide (CHX). MYC protein expression was assessed by Western blot using 
samples collected at the indicated time points. In both cell lines, MALT1 inhibition 
resulted in a reduced half-life of MYC protein. (C) Mino, Rec-1 and SP53 cells were 
treated with z-VRPR-fmk or DMSO and subsequently with MG132 or DMSO. MYC 
protein levels were increased by MG132 treatment as evaluated by Western blotting. 
(D) In Rec-1, SP53, Maver-1 and Z-138 cells either a control shRNA against MSMO1 
or one of the two MALT1 shRNAs were induced with doxycycline for 24 hours. 
Subsequently cells were treated with MG132 or DMSO. MYC protein levels were 
increased by MG132 treatment in MALT1-activated MCLs (Rec-1 and SP53), but not 
in MALT1-inactive MCLs (Maver-1 and Z-138) as evaluated by Western blotting. 
Figure 6. MYC expression in MCL. (A) Western blot analysis of MYC expression in 
ten MCL cell lines and in the MM cell line U266. All MCL cell lines had detectable 
MYC expression compared to the negative control U266. (B) Immunohistochemical 
MYC staining of a MYC positive MCL case (left picture; original magnification ×400) 
and a MYC negative MCL case (right picture; original magnification ×400). Images 
were captured using an Olympus BX51 microscope (Olympus, Tokio, Japan) 
equipped with an Olympus DP73 camera (Olympus) and were processed with 
Olympus cellSens software (Olympus). (C) Frequency of MYC expression in MCL. 
(D) Mean MYC expression in cytological MCL variants. MYC expression was 
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significantly higher in pleomorphic and blastoid variants compared to classical MCLs. 
Error bars indicate the standard errors of the mean. 
Figure 7. MCLs depend on MYC signaling. (A) shRNA-mediated MYC knockdown 
induced cytotoxicity in MCL cell lines. A previously described non-toxic shRNA 
against MSMO1 did not induce toxicity in any cell line. Data are shown as means ± 
standard deviation of at least three independent experiments. (B) Expression of a 
MYC cDNA rescued Jeko-1, Rec-1, and SP53 cells transduced with MYC shRNA #2 
(targeting the 3’UTR of MYC) from toxicity. Data are shown as means ± standard 
deviation of at least two independent experiments. (C) Expression of a MYC cDNA 
partially rescued Jeko-1, Rec-1, and SP53 cells transduced with MALT1 shRNA #1 
from toxicity. Data are shown as means ± standard deviation of at least two 
independent experiments. (D) Expression of a MYC cDNA partially rescued Jeko-1, 
Rec-1, SP53, and Mino cells treated with z-VRPR-fmk from toxicity. Data are shown 
as means ± standard deviation of at least two independent experiments. (E) shRNA-
mediated knockdown of MYC significantly downregulated cell proliferation. Data are 
shown as means ± standard deviation of at least two independent experiments. (F) 
Correlation of Ki-67 and MYC expression determined by immunohistochemistry. Error 
bars indicate the standard errors of the mean. (G) Viability of MCL cell lines following 
MYC inhibition using the small molecule inhibitor 10058-F4 that inhibits MYC-MAX 
heterodimerization. Baseline MYC expression was assessed by Western blotting 
(Figure 6A). Representative results from at least three independent replicates are 
shown. Error bars indicate the standard deviation. 
* P < .05, ** P < .01, *** P < .001.
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B-cell receptor driven MALT1 activity regulates MYC signaling in 
mantle cell lymphoma 
 
Supplemental Material and Methods 
 
Immunohistochemistry 
Five reactive lymph node and tonsil specimens, 234 formalin-fixed, paraffin-
embedded (FFPE) mantle cell lymphoma (MCL) samples, 93 diffuse large B-cell 
lymphoma (DLBCL) samples and seven Burkitt lymphoma (BL) samples were 
analyzed by immunohistochemistry. MYC staining was performed as described.1 A 
cut-off level of ≥30% tumor cells with distinct nuclear staining was applied to define 
MYC positivity.1,2 Samples with <10% positive cells were defined as MYC negative. 
Samples with ≥10% and <30% positive cells were determined as MYC intermediate 
positive. Ki-67 staining was done as described.3 MALT1 immunohistochemistry was 
performed using the anti-human MALT1 antibody clone 50 (AbD Serotec, Puchheim, 
Germany) or the anti-human MALT1 antibody MT1/410 (Abcam, Cambridge, UK). 
 
Cell culture, retroviral constructs and transductions 
The human MCL cell lines Mino, Jeko-1, Rec-1, SP49, SP53, Z-138, Maver-1, and 
Granta-519 were cultured in RPMI 1640 with 10% or 20% fetal calf serum. Two MCL 
cell lines JVM-2 and JVM-13 as well as the multiple myeloma (MM) cell line U266 
were cultured in Iscove´s modified Dulbecco´s medium supplemented with 20% 
human plasma. All cell lines were maintained at 37°C with 5% CO2. 
 For efficient retroviral transductions, all cell lines were engineered to express 
the murine ecotropic receptor as previously described.4,5 Additionally, these cell lines 
were engineered to express the bacterial tetracycline repressor allowing doxycycline-
2 
 
inducible small hairpin RNA (shRNA) or complementary DNA (cDNA) expression.4,5 
The shRNA-mediated RNA interference and cytotoxicity assays were performed as 
described.4,5 In brief, to assess toxicity of the shRNA, retroviruses that co-express 
green fluorescent protein (GFP) were used. Flow cytometry was performed two days 
after shRNA transduction to determine the initial GFP-positive proportion of live cells 
for each shRNA. Subsequently, cells were cultured with doxycycline (20 ng/mL) to 
induce shRNA expression and sampled over time. The GFP-positive proportion at 
each time point was normalized to that of the day two fraction. The targeting 
sequence of the utilized shRNAs directed against BCL10, CARD11, CD79A, MALT1 
and MYC are summarized in Supplemental Table 1. As a negative control shRNA, 
we used a previously described shRNA against MSMO1 (Supplemental Table 1).5 
Each shRNA experiment was performed at least three times for each cell line. For the 
MALT1 and MYC rescue experiments a MALT1 cDNA (NM_006785.3) and a MYC 
cDNA (NM_002467.2) were created and the experiment was performed as 
described.5,6 The MALT1 rescue experiment was performed at least three times and 
the MYC rescue experiment at least two times. Expression of the BTKC481S cDNA in 
Mino, Jeko-1, Rec-1, SP49, SP53, Z-138 and Maver-1 cells was performed as 
described.7 
 
Isolation and stimulation of mouse splenocytes 
Primary mouse splenocytes were isolated from C57/BL6 littermates expressing either 
wild-type MALT1 (+/+) or a catalytically inactive C472A mutant of MALT1 (ki/ki) as 
described.8 Splenocyte stimulation was initiated by addition of phorbol myristate 
acetate (PMA; 80 ng/mL; Alexis, Enzo Life Sciences, Lausen, Switzerland) and 
ionomycin (1 μM; Calbiochem, Merck, Darmstadt, Germany) and cells were 
incubated for the indicated times at 37°C.  
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In vivo xenograft mouse studies 
For in vivo testing of the Jeko-1 xenograft mouse models, six to eight week old 
female NOD.Cg-Prkdc severe combined immunodeficiency Il2rgtm1Wjl/SzJ (NSG; 
Jackson Laboratory, Bar Harbor, ME, USA) mice were used. To induce either MALT1 
shRNA #2 or the non-toxic shRNA against MSMO1, mice received drinking water 
supplemented with 1 mg/mL doxycycline (Genaxxon, Ulm, Germany) and 5% 
sucrose immediately after they developed macroscopic signs of s.c. tumors. Tumor 
size was measured three times weekly in two dimensions for each mouse using 
caliper. Tumor volume was calculated according to the following formula: 1/2 × 
(length × width2). All animal experiments were approved by the institutional Animal 
Care and Use Committee, as well as by the Research and Higher Education section 
of the Ministry of Education, Youth and Sports of the Czech Republic under the 
number 592/15 (MSMT-11255/2015-4). 
 
Viability assay, analysis of cell cycle, apoptosis, proliferation 
MCL cell lines were incubated with different concentrations of z-VRPR-fmk (Bachem, 
Bubendorf, Switzerland), 10058-F4 (Sigma-Aldrich, Schnelldorf, Germany), ibrutinib 
(Selleckchem, Houston, TX, USA), and doxorubicin (Sigma-Aldrich). Cell viability was 
measured after three days (doxorubicin and 10058-F4), five days (ibrutinib) or seven 
days (z-VRPR-fmk) of incubation using the Cell Titer Glo Assay (Promega, 
Dübendorf, Switzerland) as previously described.5,9 Each experiment was 
reproduced at least two times for each cell line. 
The number of cell divisions following treatment with z-VRPR-fmk or DMSO was 
quantified by using the following equation and stated as mean ± standard deviation of 
at least three independent experiments for each cell line. 
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Nt=N02tf 
Variables: 
Nt Numbers of cells at time t 
N0 Numbers of cells initially 
t Time (days) 
f Frequency of cell division per day 
 
Gene expression profiling 
Gene expression profiling was performed 24, 30, 36, 42, 48, and 54 hours following 
treatment with z-VRPR-fmk or DMSO in cell lines Mino and Rec-1 as previously 
described.10 Total RNA was isolated using the NucleoSpin RNA II Kit (Macherey & 
Nagel, Oensingen, Switzerland) according to the manufacturer's protocol. RNA was 
amplified and labeled with the TotalPrep RNA Amplification Kit (Illumina, Thermo 
Fisher Scientific, Waltham, MA, USA). Samples were subsequently hybridized on 
HumanHT-12 v4 Expression Bead Chips (Illumina) following the manufacturer's 
protocol as previously described.10,11 Gene expression changes were measured in 
two independent biological replicates for each time point in Mino cells and in one 
experiment in Rec-1 cells. Gene expression changes in Mino and Rec-1 cells treated 
with z-VRPR-fmk were compared to cells treated with DMSO. The independent 
measurements were preprocessed and normalized in the following manner. Data 
were imported on raw bead level and subsequently a bead level spot filter was 
applied to each microarray experiment based on the fitted density mode for the 
background intensities. Afterwards, bead intensities of all measured microarrays 
were quantile-normalized and beads were grouped by measured sequence to form 
beadsets. Beadsets with more than 50% of their beads excluded by the spot filter 
were also excluded. Further analyses were performed on gene level using median 
aggregation and manufacturer’s annotations. 
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Differentially expressed genes were identified in the following manner. A one-
tailed paired t-test was used to calculate P-values for each gene based on all the 
microarray pairs. Additionally, we used the Benjamini & Hochberg method to 
calculate a false discovery rate (FDR) for every significance threshold. In Rec-1 cells, 
we identified 113 genes that were significantly downregulated (P ≤ .0025; FDR = .09) 
and 223 genes that were significantly upregulated (P ≤ .0025; FDR = .05) across all 
time points following inhibition of MALT1 (paired t-tests over all time points of on one 
experiment; Supplemental Table 5). In Mino cells, we identified 93 genes that were 
significantly downregulated (P ≤ 1×10−5; FDR = .0002) and 126 genes that were 
significantly upregulated (P ≤ 1×10−5; FDR = .0001) across all time points following 
inhibition of MALT1 (paired t-tests over all time points of two independent replicates; 
Supplemental Table 2). 
 The gene set enrichment analysis (GSEA) was performed as previously 
described against an integrated database with 13,593 gene signatures, comprised of 
signatures from the Molecular Signatures Database v4, the GeneSigDB v4, HGCN 
gene families and the Staudt laboratory library.12-16 Signatures with less than eight 
measured genes were excluded. GSEA P-values were computed by permutation 
tests and FDRs were computed relative to respective signature families. Top 
enriched signatures with an absolute enrichment score ≥ .7 in cell lines Mino and 
Rec-1 after treatment with z-VRPR-fmk are presented in Supplemental Table 3 and 
6, respectively. 
 
Western blotting and analysis of MYC stability 
Western blotting was performed as described.5 Image acquisition was performed 
using Amersham Imager 600 (GE Healthcare Life Sciences, Chicago, IL, USA). Band 
quantification was performed using the ImageQuant TL software (GE Healthcare Life 
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Sciences). All antibodies used in this study were obtained from Cell Signaling 
(Danvers, MA, USA) except of antibodies detecting A20, full-length BCL10, MYC 
(Abcam, Cambridge, UK), and α-Tubulin (Sigma-Aldrich). Antibodies directed against 
cleaved BCL10 and MALT1 have been previously described.17,18 Full-length and 
cleaved isoforms of RelB, A20 and CYLD were detected with the same antibody, 
whereas full-length and cleaved forms of BCL10 were detected with different 
antibodies as stated above.  
 Non-transduced cells treated with z-VRPR-fmk (50 μM) or DMSO for the 
indicated time points or cells transduced with inducible MALT1 shRNAs and treated 
with doxocycline for 24 hours were incubated with 5 μM MG132 (Selleckchem, 
Houston, TX, USA) or 10 μg/mL cycloheximide (Santa Cruz Biotechnology, 
Heidelberg, Germany) at 37°C, harvested, and subjected to immunoblotting. 
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Supplemental Figures 
 
Supplemental Figure 1. MALT1 expression in normal reactive tissue. 
Immunohistochemical MALT1 staining of a reactive tonsil specimen (original 
magnification ×200). Image was captured using an Olympus BX51 microscope 
(Olympus, Tokio, Japan) equipped with an Olympus DP73 camera (Olympus) and 
was processed with Olympus cellSens software (Olympus). 
 
Supplemental Figure 2. Toxicity of shRNA-mediated knockdown of BCL10 in 
MCL cell lines. (A) A BCL10 shRNA downregulates BCL10 protein in MALT1-
activated (Jeko-1 and Rec-1) and MALT1-inactive (Maver-1 and Z-138) MCLs 48 
hours after shRNA induction measured by Western blotting. (B) BCL10 knockdown 
induced toxicity in MALT1-activated MCLs (Jeko-1 and Rec-1), whereas it did not 
affect MALT1-inactive MCLs (Maver-1 and Z-138). A previously described non-toxic 
shRNA against MSMO1 did not induce toxicity in any cell line. Data are shown as 
means ± standard deviation of at least three independent experiments. 
 
Supplemental Figure 3. Cell cycle analysis following pharmacologic MALT1 
inhibition. Cell cycle distribution of Mino and Z-138 cells after treatment with z-
VRPR-fmk or DMSO alone was measured on day zero and after two, four, and six 
days. In both Mino and Z-138 cells no difference in cell cycle distribution was 
detectable. Data are expressed as means ± standard deviation of at least two 
independent experiments. 
 
Supplemental Figure 4. Inhibition of MALT1 overcomes BTKC481S-induced 
ibrutinib resistance in MALT1-activated MCLs. Western blotting for FLAG and 
10 
 
BTK following transduction of MCL cells with either a BTKC481S cDNA or an empty 
vector (A. Jeko-1; C. Rec-1; E. SP53; G. SP49; I. Maver-1; K. Z-138). Determination 
of cell viability of MCL cells expressing either an empty vector (red) or a BTKC481S 
cDNA (blue) following treatment with ibrutinib or z-VRPR-fmk (B. Jeko-1; D. Rec-1; F. 
SP53; H. SP49; J. Maver-1; L. Z-138). Representative results from at least two 
independent replicates are shown. Error bars indicate the standard deviation. 
 
Supplemental Figure 5. Inhibition of MALT1 suppresses the gene expression 
network of MYC in Mino cells. (A) Gene expression profiling following MALT1 
inhibition in Mino cells. Changes of gene expression were profiled at the indicated 
time points following treatment with z-VRPR-fmk relative to treatment with DMSO 
only. Each time point depicted the mean of log2-transformed expression ratios for two 
replicates according to the color scale shown. (B) Inhibition of MALT1 significantly 
downregulated the previously identified MYC target gene signature 
“COLLER_MYC_TARGETS_UP”. Changes of gene expression were profiled at the 
indicated time points following inhibition of MALT1. Each time point depicted the 
mean of log2-transformed expression ratios for two replicates. Gene expression 
changes were depicted according to the color scale shown. 
 
Supplemental Figure 6. Inhibition of MALT1 suppresses the gene expression 
network of MYC in Rec-1 cells. (A) Gene expression profiling following 
pharmacologic inhibition of the proteolytic MALT1 activity using z-VRPR-fmk vs. 
DMSO in Rec-1 cells. Changes of gene expression were profiled at the indicated time 
points following treatment with z-VRPR-fmk. Gene expression changes are depicted 
according to the color scale shown. Genes that are involved in critical biological 
processes are highlighted. (B) Gene expression profiling following MALT1 inhibition 
11 
 
in Rec-1 cells. Changes of gene expression were profiled at the indicated time points 
following treatment with z-VRPR-fmk relative to treatment with DMSO only. Gene 
expression changes are depicted according to the color scale shown. A fraction of 
genes that were also upregulated in Mino cells following MALT1 inhibition are 
highlighted. (C) Gene set enrichment analysis of a previously described MYC gene 
expression signature. The MYC signature was significantly enriched with genes that 
are downregulated following pharmacologic MALT1 inhibition using z-VRPR-fmk in 
Rec-1 cells. (D) Inhibition of MALT1 significantly downregulated the previously 
identified MYC target gene signature “COLLER_MYC_TARGETS_UP” in Rec-1 cells. 
Changes of gene expression were profiled at the indicated time points following 
inhibition of MALT1. Gene expression changes were depicted according to the color 
scale shown. (E) Downregulation of the Mino target gene signature (Figure 4A) in 
Rec-1 cells. Changes of gene expression were profiled at the indicated time points 
following treatment with z-VRPR-fmk relative to treatment with DMSO only. Gene 
expression changes are depicted according to the color scale shown. Genes that are 
highlighted in Figure 4A are also highlighted here. 
 
Supplemental Figure 7. Expression levels of MALT1 target genes in MALT1-
activated and -inactive MCL cell lines following MALT1 inhibition. mRNA levels 
of ITPKA, MAPK13, PVT1, ETS2, NAMPT, KIF26B, C10orf10, and ALKBH2 in the 
indicated MCL cell lines following MALT1 inhibition were normalized to expression of 
GAPDH. Error bars indicate the standard deviation.  
N.D., not detectable, N.S., not significant, * P < .05, ** P < .01, *** P < .001. 
 
Supplemental Figure 8. Downregulation of MYC protein expression in MALT1-
activated MCLs following ibrutinib treatment. MYC expression on protein level 
12 
 
was downregulated in MALT1-activated MCLs (Mino and Rec-1), but not in MALT1-
inactive MCLs (Maver-1 and Z-138) following Bruton’s tyrosine kinase (BTK) 
inhibition using the small molecule inhibitor ibrutinib. 
 
Supplemental Figure 9. Protein quantification of Western blot data depicted in 
Figure 5B and 5C. (A) Protein quantification of Western blot of Figure 5B. The MYC 
measurements of cells incubated with cycloheximide (CHX) were normalized to 
matched tubulin measurements and then depicted as a ratio of the normalized values 
of cells without CHX incubation. (B) Protein quantification of Western blot of Figure 
5C.  At indicated time points, the MYC measurements of cells treated with z-VRPR-
fmk were normalized to matched tubulin measurements and then shown as a ratio of 
the normalized values of cells treated with DMSO.  
 
Supplemental Figure 10. Protein quantification of Western blot data depicted in 
Figure 6A. For all cell lines MYC measurements were normalized to matched tubulin 
measurements and then depicted as fold change compared to the normalized values 
of U266 cells.  
 
Supplemental Figure 11. MYC expression in MYC positive lymphomas. 
Immunohistochemical MYC staining of a BL case (left picture; original magnification 
×400) and a DLBCL case (right picture; original magnification ×400). Images were 
captured using an Olympus BX51 microscope (Olympus) equipped with an Olympus 
DP73 camera (Olympus) and were processed with Olympus cellSens software 
(Olympus). 
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Supplemental Figure 12. Functional role of MYC in MCL. (A) MYC shRNA #1 and 
#2 significantly downregulated MYC protein measured by Western blotting in Rec-1 
and SP53 cells. (B) Expression of a MYC cDNA partially rescued Jeko-1, Rec-1, and 
SP53 cells transduced with MALT1 shRNA #2 from toxicity. Data are shown as 
means ± standard deviation of at least two independent experiments. (C) Expression 
of a MYC cDNA did not rescue Jeko-1, Rec-1, SP53, and Mino cells treated with 
doxorubicin for 72 hours from toxicity. Representative results from two independent 
replicates are shown. Error bars indicate the standard deviation. (D) Correlation of 
MYC and Ki-67 expression in MCL (r = .63; P = 5×10−27). 
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Target gene shRNA sequence
BCL10 shRNA #1: GATGAAGTGCTGAAACTTAGA​
CARD11 shRNA #1: GGGGTGTGTACCAGGCTATGA
CARD11 shRNA #2: GGACGACAACTACAACTTAGC
CD79A shRNA #1: GGGGCTTCCTTAGTCATATTC
CD79A shRNA #2: CAGCGGGTAATGAGCCCTTAA
MALT1 shRNA #1: GGCAGCTACTTGGTATCAAAG
MALT1 shRNA #2: GTCACAGAATTGAGTGATTTC
MSMO1 shRNA #1: GGATAATGGTGATTGAGATGG
MYC shRNA #1: CGATTCCTTCTAACAGAAATG
MYC shRNA #2: CCTATGAACTTGTTTCAAATG
Supplemental Table 1. Sequences of utilized shRNAs.
Supplemental Table 2. Downregulated and upregulated genes following z-VRPR-fmk treatment in Mino cells.
Signature name Gene symbol Gene ID Gene description
Downregulated genes (alpha=1e-05) ADAP2 55803 ArfGAP with dual PH domains 2
Downregulated genes (alpha=1e-05) ADM 133 adrenomedullin
Downregulated genes (alpha=1e-05) ADTRP 84830 androgen-dependent TFPI-regulating protein
Downregulated genes (alpha=1e-05) AK2 204 adenylate kinase 2
Downregulated genes (alpha=1e-05) ALKBH2 121642 alkB, alkylation repair homolog 2 (E. coli)
Downregulated genes (alpha=1e-05) ASS1P11 340274 argininosuccinate synthetase 1 pseudogene 11
Downregulated genes (alpha=1e-05) BSPRY 54836 B-box and SPRY domain containing
Downregulated genes (alpha=1e-05) C10orf10 11067 chromosome 10 open reading frame 10
Downregulated genes (alpha=1e-05) C1orf186 440712 chromosome 1 open reading frame 186
Downregulated genes (alpha=1e-05) C9orf173 441476 chromosome 9 open reading frame 173
Downregulated genes (alpha=1e-05) CAMP 820 cathelicidin antimicrobial peptide
Downregulated genes (alpha=1e-05) CARD9 64170 caspase recruitment domain family, member 9
Downregulated genes (alpha=1e-05) CD247 919 CD247 molecule
Downregulated genes (alpha=1e-05) CHCHD10 400916 coiled-coil-helix-coiled-coil-helix domain containing 10
Downregulated genes (alpha=1e-05) CHCHD6 84303 coiled-coil-helix-coiled-coil-helix domain containing 6
Downregulated genes (alpha=1e-05) CHDH 55349 choline dehydrogenase
Downregulated genes (alpha=1e-05) CHST7 56548 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7
Downregulated genes (alpha=1e-05) COL9A2 1298 collagen, type IX, alpha 2
Downregulated genes (alpha=1e-05) CXCR7 57007 chemokine (C-X-C motif) receptor 7
Downregulated genes (alpha=1e-05) DNASE1L3 1776 deoxyribonuclease I-like 3
Downregulated genes (alpha=1e-05) ETS2 2114 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)
Downregulated genes (alpha=1e-05) FAM46C 54855 family with sequence similarity 46, member C
Downregulated genes (alpha=1e-05) FAM81A 145773 family with sequence similarity 81, member A
Downregulated genes (alpha=1e-05) FKBP11 51303 FK506 binding protein 11, 19 kDa
Downregulated genes (alpha=1e-05) GCSH 2653 glycine cleavage system protein H (aminomethyl carrier)
Downregulated genes (alpha=1e-05) GLT25D2 23127 glycosyltransferase 25 domain containing 2
Downregulated genes (alpha=1e-05) HEY2 23493 hairy/enhancer-of-split related with YRPW motif 2
Downregulated genes (alpha=1e-05) IL17RB 55540 interleukin 17 receptor B
Downregulated genes (alpha=1e-05) ITPKA 3706 inositol-trisphosphate 3-kinase A
Downregulated genes (alpha=1e-05) KIF26B 55083 kinesin family member 26B
Downregulated genes (alpha=1e-05) KISS1R 84634 KISS1 receptor
Downregulated genes (alpha=1e-05) KLHL14 57565 kelch-like 14 (Drosophila)
Downregulated genes (alpha=1e-05) LMO3 55885 LIM domain only 3 (rhombotin-like 2)
Downregulated genes (alpha=1e-05) LMO7 4008 LIM domain 7
Downregulated genes (alpha=1e-05) LOC100132439100132439 protein FAM27E3-like
Downregulated genes (alpha=1e-05) LOC284837 284837 uncharacterized LOC284837
Downregulated genes (alpha=1e-05) LOC642661 642661 translocase of outer mitochondrial membrane 40 homolog (yeast) pseudogene
Downregulated genes (alpha=1e-05) LOC645638 645638 WDNM1-like pseudogene
Downregulated genes (alpha=1e-05) MAPK13 5603 mitogen-activated protein kinase 13
Downregulated genes (alpha=1e-05) MLKL 197259 mixed lineage kinase domain-like
Downregulated genes (alpha=1e-05) MS4A6A 64231 membrane-spanning 4-domains, subfamily A, member 6A
Downregulated genes (alpha=1e-05) MSRB1 51734 methionine sulfoxide reductase B1
Downregulated genes (alpha=1e-05) NAMPT 10135 nicotinamide phosphoribosyltransferase
Downregulated genes (alpha=1e-05) NOD2 64127 nucleotide-binding oligomerization domain containing 2
Downregulated genes (alpha=1e-05) NPM3 10360 nucleophosmin/nucleoplasmin 3
Downregulated genes (alpha=1e-05) NPW 283869 neuropeptide W
Downregulated genes (alpha=1e-05) NRARP 441478 NOTCH-regulated ankyrin repeat protein
Downregulated genes (alpha=1e-05) NRG4 145957 neuregulin 4
Downregulated genes (alpha=1e-05) PDCD2L 84306 programmed cell death 2-like
Downregulated genes (alpha=1e-05) PDE7B 27115 phosphodiesterase 7B
Downregulated genes (alpha=1e-05) PFKM 5213 phosphofructokinase, muscle
Downregulated genes (alpha=1e-05) PIEZO1 9780 piezo-type mechanosensitive ion channel component 1
Downregulated genes (alpha=1e-05) PNMA3 29944 paraneoplastic Ma antigen 3
Downregulated genes (alpha=1e-05) PNP 4860 purine nucleoside phosphorylase
Downregulated genes (alpha=1e-05) POLR1C 9533 polymerase (RNA) I polypeptide C, 30kDa
Downregulated genes (alpha=1e-05) POLR3G 10622 polymerase (RNA) III (DNA directed) polypeptide G (32kD)
Downregulated genes (alpha=1e-05) PPAN 56342 peter pan homolog (Drosophila)
Downregulated genes (alpha=1e-05) PPAN-P2RY11 692312 PPAN-P2RY11 readthrough
Downregulated genes (alpha=1e-05) PRMT1 3276 protein arginine methyltransferase 1
Downregulated genes (alpha=1e-05) PVT1 5820 Pvt1 oncogene (non-protein coding)
Downregulated genes (alpha=1e-05) RAB40B 10966 RAB40B, member RAS oncogene family
Downregulated genes (alpha=1e-05) RGS16 6004 regulator of G-protein signaling 16
Downregulated genes (alpha=1e-05) RPF2P1 729608 ribosome production factor 2 homolog (S. cerevisiae) pseudogene 1
Downregulated genes (alpha=1e-05) RPL29 6159 ribosomal protein L29
Downregulated genes (alpha=1e-05) RPS7 6201 ribosomal protein S7
Downregulated genes (alpha=1e-05) RSPH1 89765 radial spoke head 1 homolog (Chlamydomonas)
Downregulated genes (alpha=1e-05) RXRA 6256 retinoid X receptor, alpha
Downregulated genes (alpha=1e-05) SEPT3 55964 septin 3
Downregulated genes (alpha=1e-05) SEPW1 6415 selenoprotein W, 1
Downregulated genes (alpha=1e-05) SH3TC1 54436 SH3 domain and tetratricopeptide repeats 1
Downregulated genes (alpha=1e-05) SLC16A9 220963 solute carrier family 16, member 9 (monocarboxylic acid transporter 9)
Downregulated genes (alpha=1e-05) SLC25A12 8604 solute carrier family 25 (aspartate/glutamate carrier), member 12
Downregulated genes (alpha=1e-05) SLC27A5 10998 solute carrier family 27 (fatty acid transporter), member 5
Downregulated genes (alpha=1e-05) SLC2A5 6518 solute carrier family 2 (facilitated glucose/fructose transporter), member 5
Downregulated genes (alpha=1e-05) SNAPC4 6621 small nuclear RNA activating complex, polypeptide 4, 190kDa
Downregulated genes (alpha=1e-05) SNORA24 677809 small nucleolar RNA, H/ACA box 24
Downregulated genes (alpha=1e-05) SNORA56 677835 small nucleolar RNA, H/ACA box 56
Downregulated genes (alpha=1e-05) SNORA64 26784 small nucleolar RNA, H/ACA box 64
Downregulated genes (alpha=1e-05) SNORD16 595097 small nucleolar RNA, C/D box 16
Downregulated genes (alpha=1e-05) SNORD65 692106 small nucleolar RNA, C/D box 65
Downregulated genes (alpha=1e-05) SNORD80 26774 small nucleolar RNA, C/D box 80
Downregulated genes (alpha=1e-05) SNORD83B 116938 small nucleolar RNA, C/D box 83B
Downregulated genes (alpha=1e-05) SNORD96A 619571 small nucleolar RNA, C/D box 96A
Downregulated genes (alpha=1e-05) SPINK2 6691 serine peptidase inhibitor, Kazal type 2 (acrosin-trypsin inhibitor)
Downregulated genes (alpha=1e-05) SULF2 55959 sulfatase 2
Downregulated genes (alpha=1e-05) SUSD2 56241 sushi domain containing 2
Downregulated genes (alpha=1e-05) SYTL3 94120 synaptotagmin-like 3
Downregulated genes (alpha=1e-05) TIGIT 201633 T cell immunoreceptor with Ig and ITIM domains
Downregulated genes (alpha=1e-05) TLCD1 116238 TLC domain containing 1
Downregulated genes (alpha=1e-05) TM2D3 80213 TM2 domain containing 3
Downregulated genes (alpha=1e-05) TNFRSF13B 23495 tumor necrosis factor receptor superfamily, member 13B
Downregulated genes (alpha=1e-05) TNFRSF4 7293 tumor necrosis factor receptor superfamily, member 4
Downregulated genes (alpha=1e-05) WNT10A 80326 wingless-type MMTV integration site family, member 10A
Upregulated genes (alpha=1e-05) ABCA1 19 ATP-binding cassette, sub-family A (ABC1), member 1
Upregulated genes (alpha=1e-05) ABHD8 79575 abhydrolase domain containing 8
Upregulated genes (alpha=1e-05) ADARB1 104 adenosine deaminase, RNA-specific, B1
Upregulated genes (alpha=1e-05) ALDH5A1 7915 aldehyde dehydrogenase 5 family, member A1
Upregulated genes (alpha=1e-05) APOC2 344 apolipoprotein C-II
Upregulated genes (alpha=1e-05) APOD 347 apolipoprotein D
Upregulated genes (alpha=1e-05) ARSD 414 arylsulfatase D
Upregulated genes (alpha=1e-05) BACH2 60468 BTB and CNC homology 1, basic leucine zipper transcription factor 2
Upregulated genes (alpha=1e-05) BEST3 144453 bestrophin 3
Upregulated genes (alpha=1e-05) BHLHE40 8553 basic helix-loop-helix family, member e40
Upregulated genes (alpha=1e-05) C12orf57 113246 chromosome 12 open reading frame 57
Upregulated genes (alpha=1e-05) C16orf93 90835 chromosome 16 open reading frame 93
Upregulated genes (alpha=1e-05) CAND2 23066 cullin-associated and neddylation-dissociated 2 (putative)
Upregulated genes (alpha=1e-05) CASZ1 54897 castor zinc finger 1
Upregulated genes (alpha=1e-05) CBLB 868 Cbl proto-oncogene, E3 ubiquitin protein ligase B
Upregulated genes (alpha=1e-05) CCNG2 901 cyclin G2
Upregulated genes (alpha=1e-05) CD24 100133941 CD24 molecule
Upregulated genes (alpha=1e-05) CD72 971 CD72 molecule
Upregulated genes (alpha=1e-05) CD81 975 CD81 molecule
Upregulated genes (alpha=1e-05) CDKN2D 1032 cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Upregulated genes (alpha=1e-05) CIITA 4261 class II, major histocompatibility complex, transactivator
Upregulated genes (alpha=1e-05) CNR1 1268 cannabinoid receptor 1 (brain)
Upregulated genes (alpha=1e-05) COQ10A 93058 coenzyme Q10 homolog A (S. cerevisiae)
Upregulated genes (alpha=1e-05) CXCL16 58191 chemokine (C-X-C motif) ligand 16
Upregulated genes (alpha=1e-05) CXCR4 7852 chemokine (C-X-C motif) receptor 4
Upregulated genes (alpha=1e-05) CYFIP2 26999 cytoplasmic FMR1 interacting protein 2
Upregulated genes (alpha=1e-05) DDX54 79039 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54
Upregulated genes (alpha=1e-05) DENND2A 27147 DENN/MADD domain containing 2A
Upregulated genes (alpha=1e-05) DENND2D 79961 DENN/MADD domain containing 2D
Upregulated genes (alpha=1e-05) DFNA5 1687 deafness, autosomal dominant 5
Upregulated genes (alpha=1e-05) DOK3 79930 docking protein 3
Upregulated genes (alpha=1e-05) EBF1 1879 early B-cell factor 1
Upregulated genes (alpha=1e-05) EMP3 2014 epithelial membrane protein 3
Upregulated genes (alpha=1e-05) EPSTI1 94240 epithelial stromal interaction 1 (breast)
Upregulated genes (alpha=1e-05) ETV5 2119 ets variant 5
Upregulated genes (alpha=1e-05) FBXO32 114907 F-box protein 32
Upregulated genes (alpha=1e-05) FCGRT 2217 Fc fragment of IgG, receptor, transporter, alpha
Upregulated genes (alpha=1e-05) FLJ42627 645644 uncharacterized LOC645644
Upregulated genes (alpha=1e-05) GBE1 2632 glucan (1,4-alpha-), branching enzyme 1
Upregulated genes (alpha=1e-05) GLRX 2745 glutaredoxin (thioltransferase)
Upregulated genes (alpha=1e-05) GLRXP3 100132510 glutaredoxin (thioltransferase) pseudogene 3
Upregulated genes (alpha=1e-05) GM2A 2760 GM2 ganglioside activator
Upregulated genes (alpha=1e-05) GNG7 2788 guanine nucleotide binding protein (G protein), gamma 7
Upregulated genes (alpha=1e-05) GPR160 26996 G protein-coupled receptor 160
Upregulated genes (alpha=1e-05) GPR18 2841 G protein-coupled receptor 18
Upregulated genes (alpha=1e-05) HBEGF 1839 heparin-binding EGF-like growth factor
Upregulated genes (alpha=1e-05) HCP5 10866 HLA complex P5 (non-protein coding)
Upregulated genes (alpha=1e-05) HES6 55502 hairy and enhancer of split 6 (Drosophila)
Upregulated genes (alpha=1e-05) HLA-DPA1 3113 major histocompatibility complex, class II, DP alpha 1
Upregulated genes (alpha=1e-05) HLA-DPB1 3115 major histocompatibility complex, class II, DP beta 1
Upregulated genes (alpha=1e-05) HLA-DRA 3122 major histocompatibility complex, class II, DR alpha
Upregulated genes (alpha=1e-05) IRF1 3659 interferon regulatory factor 1
Upregulated genes (alpha=1e-05) IRF9 10379 interferon regulatory factor 9
Upregulated genes (alpha=1e-05) KIAA1683 80726 KIAA1683
Upregulated genes (alpha=1e-05) KLF2 10365 Kruppel-like factor 2 (lung)
Upregulated genes (alpha=1e-05) KLHL22 84861 kelch-like 22 (Drosophila)
Upregulated genes (alpha=1e-05) KLHL24 54800 kelch-like 24 (Drosophila)
Upregulated genes (alpha=1e-05) KLHL6 89857 kelch-like 6 (Drosophila)
Upregulated genes (alpha=1e-05) LAMP5 24141 lysosomal-associated membrane protein family, member 5
Upregulated genes (alpha=1e-05) LGALS1 3956 lectin, galactoside-binding, soluble, 1
Upregulated genes (alpha=1e-05) LILRB4 11006 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
Upregulated genes (alpha=1e-05) LINC00426 100188949 long intergenic non-protein coding RNA 426
Upregulated genes (alpha=1e-05) LOC728743 728743 zinc finger protein pseudogene
Upregulated genes (alpha=1e-05) LRMP 4033 lymphoid-restricted membrane protein
Upregulated genes (alpha=1e-05) LY86 9450 lymphocyte antigen 86
Upregulated genes (alpha=1e-05) LYL1 4066 lymphoblastic leukemia derived sequence 1
Upregulated genes (alpha=1e-05) MDK 4192 midkine (neurite growth-promoting factor 2)
Upregulated genes (alpha=1e-05) MFGE8 4240 milk fat globule-EGF factor 8 protein
Upregulated genes (alpha=1e-05) MIS18BP1 55320 MIS18 binding protein 1
Upregulated genes (alpha=1e-05) MYB 4602 v-myb myeloblastosis viral oncogene homolog (avian)
Upregulated genes (alpha=1e-05) NINJ2 4815 ninjurin 2
Upregulated genes (alpha=1e-05) NPAS1 4861 neuronal PAS domain protein 1
Upregulated genes (alpha=1e-05) NPC2 10577 Niemann-Pick disease, type C2
Upregulated genes (alpha=1e-05) NUB1 51667 negative regulator of ubiquitin-like proteins 1
Upregulated genes (alpha=1e-05) NUCB2 4925 nucleobindin 2
Upregulated genes (alpha=1e-05) OAS1 4938 2'-5'-oligoadenylate synthetase 1, 40/46kDa
Upregulated genes (alpha=1e-05) OAS2 4939 2'-5'-oligoadenylate synthetase 2, 69/71kDa
Upregulated genes (alpha=1e-05) OAS3 4940 2'-5'-oligoadenylate synthetase 3, 100kDa
Upregulated genes (alpha=1e-05) P2RY8 286530 purinergic receptor P2Y, G-protein coupled, 8
Upregulated genes (alpha=1e-05) PARP15 165631 poly (ADP-ribose) polymerase family, member 15
Upregulated genes (alpha=1e-05) PARP9 83666 poly (ADP-ribose) polymerase family, member 9
Upregulated genes (alpha=1e-05) PARVG 64098 parvin, gamma
Upregulated genes (alpha=1e-05) PELI2 57161 pellino E3 ubiquitin protein ligase family member 2
Upregulated genes (alpha=1e-05) PPP1R16B 26051 protein phosphatase 1, regulatory subunit 16B
Upregulated genes (alpha=1e-05) PRKCE 5581 protein kinase C, epsilon
Upregulated genes (alpha=1e-05) PRR5 55615 proline rich 5 (renal)
Upregulated genes (alpha=1e-05) RARRES3 5920 retinoic acid receptor responder (tazarotene induced) 3
Upregulated genes (alpha=1e-05) RASGRP2 10235 RAS guanyl releasing protein 2 (calcium and DAG-regulated)
Upregulated genes (alpha=1e-05) RGS19 10287 regulator of G-protein signaling 19
Upregulated genes (alpha=1e-05) RHBDF1 64285 rhomboid 5 homolog 1 (Drosophila)
Upregulated genes (alpha=1e-05) RHOBTB2 23221 Rho-related BTB domain containing 2
Upregulated genes (alpha=1e-05) RNF144A 9781 ring finger protein 144A
Upregulated genes (alpha=1e-05) RNH1 6050 ribonuclease/angiogenin inhibitor 1
Upregulated genes (alpha=1e-05) RRAGD 58528 Ras-related GTP binding D
Upregulated genes (alpha=1e-05) SAMD9 54809 sterile alpha motif domain containing 9
Upregulated genes (alpha=1e-05) SAMD9L 219285 sterile alpha motif domain containing 9-like
Upregulated genes (alpha=1e-05) SASH3 54440 SAM and SH3 domain containing 3
Upregulated genes (alpha=1e-05) SETDB2 83852 SET domain, bifurcated 2
Upregulated genes (alpha=1e-05) SIT1 27240 signaling threshold regulating transmembrane adaptor 1
Upregulated genes (alpha=1e-05) SLC26A11 284129 solute carrier family 26, member 11
Upregulated genes (alpha=1e-05) SLC29A4 222962 solute carrier family 29 (nucleoside transporters), member 4
Upregulated genes (alpha=1e-05) SMAD3 4088 SMAD family member 3
Upregulated genes (alpha=1e-05) SNX29P2 440352 sorting nexin 29 pseudogene 2
Upregulated genes (alpha=1e-05) SOCS1 8651 suppressor of cytokine signaling 1
Upregulated genes (alpha=1e-05) SOX11 6664 SRY (sex determining region Y)-box 11
Upregulated genes (alpha=1e-05) SOX18 54345 SRY (sex determining region Y)-box 18
Upregulated genes (alpha=1e-05) SOX4 6659 SRY (sex determining region Y)-box 4
Upregulated genes (alpha=1e-05) SSBP2 23635 single-stranded DNA binding protein 2
Upregulated genes (alpha=1e-05) ST3GAL5 8869 ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Upregulated genes (alpha=1e-05) STK38 11329 serine/threonine kinase 38
Upregulated genes (alpha=1e-05) STMN1 3925 stathmin 1
Upregulated genes (alpha=1e-05) STS 412 steroid sulfatase (microsomal), isozyme S
Upregulated genes (alpha=1e-05) TAX1BP3 30851 Tax1 (human T-cell leukemia virus type I) binding protein 3
Upregulated genes (alpha=1e-05) TMEM136 219902 transmembrane protein 136
Upregulated genes (alpha=1e-05) TNFRSF14 8764 tumor necrosis factor receptor superfamily, member 14
Upregulated genes (alpha=1e-05) TOP2B 7155 topoisomerase (DNA) II beta 180kDa
Upregulated genes (alpha=1e-05) TP53INP1 94241 tumor protein p53 inducible nuclear protein 1
Upregulated genes (alpha=1e-05) TPP1 1200 tripeptidyl peptidase I
Upregulated genes (alpha=1e-05) TTYH3 80727 tweety homolog 3 (Drosophila)
Upregulated genes (alpha=1e-05) VPREB3 29802 pre-B lymphocyte 3
Upregulated genes (alpha=1e-05) WIPI2 26100 WD repeat domain, phosphoinositide interacting 2
Upregulated genes (alpha=1e-05) WNT3 7473 wingless-type MMTV integration site family, member 3
Upregulated genes (alpha=1e-05) YPEL5 51646 yippee-like 5 (Drosophila)
Upregulated genes (alpha=1e-05) ZEB2 9839 zinc finger E-box binding homeobox 2
Upregulated genes (alpha=1e-05) ZHX2 22882 zinc fingers and homeoboxes 2
Upregulated genes (alpha=1e-05) ZSCAN16 80345 zinc finger and SCAN domain containing 16
Signatures DB Category Sub Category Signature name Signature links
Defined 
members Enrichment score
P [GSEA]
(by permutation test) FDR [GSEA] 
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_FORMATION_OF_ATP_BY_CHEMIOSMOTIC_COUPLINGhttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_FORMATION_OF_ATP_BY_CHEMIOSMOTIC_COUPLING13 0.8416 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsCOLLER_MYC_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/COLLER_MYC_TARGETS_UP 25 0.8405 0.0010 0.0010
HGNCSigDB_dMay2014 gene families Mitochondrial ribosomal proteins Mitochondrial ribosomal proteins / small subunits http://www.genenames.org/genefamilies/MRP#MRPS 31 0.8392 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsFUNG_IL2_SIGNALING_1 http://www.broadinstitute.org/gsea/msigdb/cards/FUNG_IL2_SIGNALING_1 11 0.8324 0.0010 0.0010
HGNCSigDB_dMay2014 gene families Mitochondrial respiratory chain complexMitochondrial respiratory chain complex / Complex V http://www.genenames.org/genefamilies/mitocomplex#FATP 16 0.8277 0.0010 0.0010
HGNCSigDB_dMay2014 gene families ATPases ATPases / F-type http://www.genenames.org/genefamilies/ATP#F1ATP 15 0.8254 0.0019 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components ORGANELLAR_SMALL_RIBOSOMAL_SUBUNIT http://www.broadinstitute.org/gsea/msigdb/cards/ORGANELLAR_SMALL_RIBOSOMAL_SUBUNIT 11 0.8100 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components MITOCHONDRIAL_SMALL_RIBOSOMAL_SUBUNIT http://www.broadinstitute.org/gsea/msigdb/cards/MITOCHONDRIAL_SMALL_RIBOSOMAL_SUBUNIT11 0.8100 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components SMALL_RIBOSOMAL_SUBUNIT http://www.broadinstitute.org/gsea/msigdb/cards/SMALL_RIBOSOMAL_SUBUNIT 11 0.8100 0.0010 0.0010
HGNCSigDB_dMay2014 gene families Mitochondrial respiratory chain complexMitochondrial respiratory chain complex / Complex III http://www.genenames.org/genefamilies/mitocomplex#comIII 9 0.7990 0.0019 0.0093
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_103 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_103 12 0.7924 0.0010 0.0039
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes COENZYME_BIOSYNTHETIC_PROCESS http://www.broadinstitute.org/gsea/msigdb/cards/COENZYME_BIOSYNTHETIC_PROCESS 10 0.7862 0.0103 0.0354
HGNCSigDB_dMay2014 gene families General transcription factor IIH complex subunitsGeneral tra scription factor IIH complex subunits http://www.genenames.org/genefamilies/TFIIH 10 0.7861 0.0049 0.0086
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGYhttp://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY32 0.7853 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes PROTEIN_TARGETING_TO_MITOCHONDRION http://www.broadinstitute.org/gsea/msigdb/cards/PROTEIN_TARGETING_TO_MITOCHONDRION 11 0.7803 0.0023 0.0212
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsXU_RESPONSE_TO_TRETINOIN_AND_NSC682994_DNhttp://www.broadinstitute.org/gsea/msigdb/cards/XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_DN15 0.7791 0.0010 0.0010
StaudtSigDB_dNov2012 Signaling pathway T cell cytokine signallng Tcell_cytokine_induced_prolif http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=77 27 0.7749 0.0010 0.0010
GeneSigDB_v4_Sept2011 Mouse Lung homolog(Lung_Rangasamy09_10genes_DownRegulatedPhaseIIGenes, from Mus musculus, to Homo sapiens, 9 of 10 genes)http://www.genesigdb.org/gene igdb/signaturedet il.jsp?signatureId=19286929-SuppTable2b 9 0.7742 0.0071 0.0602
GeneSigDB_v4_Sept2011 Mouse StemCell homolog(StemCell_Parker05_27genes, from Mus musculus, to Homo sapiens, 15 of 15 genes)http://www.genesigdb.org/genesi db/signaturedetail.jsp?signatureId=15992799-table2 15 0.7702 0.0010 0.0052
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes RRNA_PROCESSING http://www.broadinstitute.org/gsea/msigdb/cards/RRNA_PROCESSING 15 0.7674 0.0012 0.0083
GeneSigDB_v4_Sept2011 Human Viral Viral_Zafrakas07_14genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=18288381-Table1 8 0.7664 0.0218 0.0370
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_50 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_50 13 0.7641 0.0011 0.0049
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes RRNA_METABOLIC_PROCESS http://www.broadinstitute.org/gsea/msigdb/cards/RRNA_METABOLIC_PROCESS 16 0.7630 0.0012 0.0059
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_471 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_471 10 0.7594 0.0094 0.0147
StaudtSigDB_dNov2012 Signaling pathway MYC Myc_overexpression_1.5x_up http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=167 86 0.7573 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components NUCLEOLAR_PART http://www.broadinstitute.org/gsea/msigdb/cards/NUCLEOLAR_PART 18 0.7532 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_MRNA_DECAY_BY_3_TO_5_EXORIBONUCLEASEhttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_MRNA_DECAY_BY_3_TO_5_EXORIBONUCLEASE11 0.7517 0.0058 0.0101
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes AMINO_ACID_DERIVATIVE_BIOSYNTHETIC_PROCESShttp://www.broadinstitute.org/gsea/msigdb/cards/AMINO_ACID_DERIVATIVE_BIOSYNTHETIC_PROCESS10 0.7482 0.0108 0.0336
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / KEGG KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIShttp://www.broadinstitute.org/gsea/msigdb/cards/KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIS11 0.7471 0.0040 0.0014
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes RIBOSOME_BIOGENESIS_AND_ASSEMBLY http://www.broadinstitute.org/gsea/msigdb/cards/RIBOSOME_BIOGENESIS_AND_ASSEMBLY 18 0.7467 0.0012 0.0032
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHUHMACHER_MYC_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/SCHUHMACHER_MYC_TARGETS_UP 80 0.7466 0.0010 0.0010
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_77 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_77 28 0.7441 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components OLIGOSACCHARYL_TRANSFERASE_COMPLEX http://www.broadinstitute.org/gsea/msigdb/cards/OLIGOSACCHARYL_TRANSFERASE_COMPLEX10 0.7370 0.0092 0.0056
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_25 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_25 13 0.7368 0.0027 0.0125
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components ORGANELLAR_RIBOSOME http://www.broadinstitute.org/gsea/msigdb/cards/ORGANELLAR_RIBOSOME 22 0.7360 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components MITOCHONDRIAL_RIBOSOME http://www.broadinstitute.org/gsea/msigdb/cards/MITOCHONDRIAL_RIBOSOME 22 0.7360 0.0010 0.0010
GeneSigDB_v4_Sept2011 Human Lymphoma Lymphoma_Cassinelli09_59genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=19555670-Table3b 49 0.7356 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes TRNA_PROCESSING http://www.broadinstitute.org/gsea/msigdb/cards/TRNA_PROCESSING 10 0.7343 0.0129 0.0470
StaudtSigDB_dNov2012 Signaling pathway Notch Notch_T-ALL_up_Palomero http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=235 47 0.7300 0.0011 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_RNA_POL_I_TRANSCRIPTION_TERMINATIONhttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_RNA_POL_I_TRANSCRIPTION_TERMINATION21 0.7294 0.0010 0.0020
HGNCSigDB_dMay2014 gene families N(alpha)-acetyltransferase subunitsN(alpha)-acetyltransferase subunits http://www.genenames.org/genefamilies/NAA 12 0.7290 0.0155 0.0111
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / KEGG KEGG_TERPENOID_BACKBONE_BIOSYNTHESIS http://www.broadinstitute.org/gsea/msigdb/cards/KEGG_TERPENOID_BACKBONE_BIOSYNTHESIS15 0.7268 0.0010 0.0021
HGNCSigDB_dMay2014 gene families Mitochondrial respiratory chain complexMitochondrial respiratory chain complex / Complex IV http://www.genenames.org/genefamilies/mitocomplex#comIV 16 0.7265 0.0010 0.0010
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_528 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_528 11 0.7254 0.0136 0.0139
GeneSigDB_v4_Sept2011 Human Breast Breast_Larsson07_76genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=17638893-SuppTable7 45 0.7200 0.0010 0.0010
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer gene neighborhoods GNF2_NS http://www.broadinstitute.org/gsea/msigdb/cards/GNF2_NS 40 0.7162 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_BRANCHED_CHAIN_AMINO_ACID_CATABOLISMhttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_BRANCHED_CHAIN_AMINO_ACID_CATABOLISM17 0.7158 0.0014 0.0070
GeneSigDB_v4_Sept2011 Mouse Bone homolog(Bone_Kalajzic05_12genes, from Mus musculus, to Homo sapiens, 10 of 11 genes)http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=15834136-Table3 10 0.7141 0.0340 0.0481
HGNCSigDB_dMay2014 gene families Mitochondrial ribosomal proteins Mitochondrial ribosomal proteins / large subunits http://www.genenames.org/genefamilies/MRP#MRPL 49 0.7141 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DNhttp://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN47 0.7138 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UPhttp://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP47 0.7127 0.0010 0.0010
GeneSigDB_v4_Sept2011 Human Breast Breast_Lee10_23genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=20068086-ST1-3 23 0.7110 0.0010 0.0013
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_MITOCHONDRIAL_TRNA_AMINOACYLATIONhttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_MITOCHONDRIAL_TRNA_AMINOACYLATION21 0.7101 0.0015 0.0017
StaudtSigDB_dNov2012 Transcription factor target PGC-1 alpha PGC-1alpha_overepxression_up http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=210 27 0.7084 0.0010 0.0010
HGNCSigDB_dMay2014 gene families Aminoacyl tRNA synthetases Aminoacyl tRNA synthetases / Class I http://www.genenames.org/genefamilies/AARS#AARS1 19 0.7048 0.0010 0.0014
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT52 0.7030 0.0010 0.0010
HGNCSigDB_dMay2014 gene families Short chain dehydrogenase Short chain dehydrogenase/reductase superfamily / Classical SDR fold cluster 1http://www.genenames.org/genefamilies/SDR#SDRC1 20 0.7024 0.0010 0.0011
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions RIBONUCLEOPROTEIN_BINDING http://www.broadinstitute.org/gsea/msigdb/cards/RIBONUCLEOPROTEIN_BINDING 12 0.7018 0.0208 0.3597
Signatures DB Category Sub Category Signature name Signature links
Defined 
members Enrichment score
P [GSEA]
(by permutation test) FDR [GSEA] 
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_293 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_293 12 -0.8842 0.0010 0.0018
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY8 -0.8811 0.0027 0.0086
HGNCSigDB_dMay2014 gene families Histocompatibility complex Histocompatibility complex http://www.genenames.org/genefamilies/HLA 24 -0.8802 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsHOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_DNhttp://www.broadinstitute.org/gsea/msigdb/cards/HOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_DN14 -0.8772 0.0010 0.0009
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_143 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_143 14 -0.8556 0.0010 0.0036
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsHOLLEMAN_DAUNORUBICIN_B_ALL_DN http://www.broadinstitute.org/gsea/msigdb/cards/HOLLEMAN_DAUNORUBICIN_B_ALL_DN 12 -0.8443 0.0010 0.0009
GeneSigDB_v4_Sept2011 Mouse Prostate homolog(Prostate_Glinsky05_11genes, from Mus musculus, to Homo sapiens, 8 of 10 genes)http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=15931389-table3 8 -0.8367 0.0060 0.0111
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHMAHL_PDGF_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/SCHMAHL_PDGF_SIGNALING 9 -0.8335 0.0011 0.0073
GeneSigDB_v4_Sept2011 Human Lymphoma Lymphoma_Fernandez10_13genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=20124476-SuppTable3 12 -0.8277 0.0010 0.0075
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes G_PROTEIN_SIGNALING_ADENYLATE_CYCLASE_INHIBITING_PATHWAYhttp://www.broadinstitute.org/gsea/msigdb/cards/G_PROTEIN_SIGNALING_ADENYLATE_CYCLASE_INHIBITING_PATHWAY10 -0.8155 0.0011 0.0310
Downregulated signatures:
Supplemental Table 3. Signatures that are significantly enriched with top regulated genes following z-VRPR-fmk treatment in Mino cells.
Upregulated signatures:
GeneSigDB_v4_Sept2011 Human Lung Lung_Nam10_10genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=20369051-Table1 9 -0.8094 0.0050 0.0122
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsMAINA_VHL_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/MAINA_VHL_TARGETS_UP 10 -0.7897 0.0022 0.0098
GeneSigDB_v4_Sept2011 Human Colon Colon_Protiva09_31genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=19139017-Table3 23 -0.7806 0.0010 0.0009
GeneSigDB_v4_Sept2011 Human Immune Immune_Ristich05_13genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=15770701-Table1 12 -0.7697 0.0033 0.0102
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions SMALL_CONJUGATING_PROTEIN_BINDING http://www.broadinstitute.org/gsea/msigdb/cards/SMALL_CONJUGATING_PROTEIN_BINDING 12 -0.7694 0.0010 0.0163
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes INTERLEUKIN_2_PRODUCTION http://www.broadinstitute.org/gsea/msigdb/cards/INTERLEUKIN_2_PRODUCTION 11 -0.7680 0.0033 0.0251
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions UBIQUITIN_BINDING http://www.broadinstitute.org/gsea/msigdb/cards/UBIQUITIN_BINDING 11 -0.7668 0.0036 0.0173
GeneSigDB_v4_Sept2011 Human Liver Liver_Liu03_11genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=14728809-Table3b 9 -0.7659 0.0034 0.0176
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_UNWINDING_OF_DNA http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_UNWINDING_OF_DNA 11 -0.7625 0.0052 0.0171
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsBOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIXhttp://www.broadinstitute.org/gsea/msigdb/cards/BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX17 -0.7620 0.0010 0.0022
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes ACTIN_FILAMENT_BASED_MOVEMENT http://www.broadinstitute.org/gsea/msigdb/cards/ACTIN_FILAMENT_BASED_MOVEMENT 10 -0.7578 0.0109 0.0342
GeneSigDB_v4_Sept2011 Human Viral Viral_Stoff-Khalili06_9genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=16410819-Table5 9 -0.7553 0.0152 0.0222
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsVISALA_AGING_LYMPHOCYTE_UP http://www.broadinstitute.org/gsea/msigdb/cards/VISALA_AGING_LYMPHOCYTE_UP 10 -0.7542 0.0105 0.0134
GeneSigDB_v4_Sept2011 Human StemCell StemCell_Novakova10_22genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=19802007-Table1 14 -0.7514 0.0020 0.0109
GeneSigDB_v4_Sept2011 Human StemCell StemCell_Lambert09_12genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=19946333-Table1 12 -0.7498 0.0010 0.0105
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsEGUCHI_CELL_CYCLE_RB1_TARGETS http://www.broadinstitute.org/gsea/msigdb/cards/EGUCHI_CELL_CYCLE_RB1_TARGETS 23 -0.7483 0.0010 0.0009
GeneSigDB_v4_Sept2011 Human Viral Viral_Guo05_21genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=16254373-Table3 18 -0.7471 0.0016 0.0067
GeneSigDB_v4_Sept2011 Human Leukemia Leukemia_Wilson06_15genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=16597596-TableS6-2 14 -0.7461 0.0017 0.0075
GeneSigDB_v4_Sept2011 Human Leukemia Leukemia_Sanchez-Guijo08_14genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=18722011-SuppTable2a 13 -0.7453 0.0084 0.0112
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsGUTIERREZ_WALDENSTROEMS_MACROGLOBULINEMIA_2http://www.broadinstitute.org/gsea/msigdb/cards/GUTIERREZ_WALDENSTROEMS_MACROGLOBULINEMIA_213 -0.7433 0.0043 0.0080
GeneSigDB_v4_Sept2011 Human Lymphoma Lymphoma_Mahadevan05_11genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=16373702-Table3 9 -0.7371 0.0217 0.0213
GeneSigDB_v4_Sept2011 Human Breast Breast_Li09_24genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=18278552-Genes 13 -0.7366 0.0051 0.0103
HGNCSigDB_dMay2014 gene families POTE ankyrin domain containing POTE ankyrin domain containing http://www.genenames.org/genefamilies/POTE 11 -0.7363 0.0091 0.0308
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / BioCarta BIOCARTA_RANKL_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_RANKL_PATHWAY 14 -0.7359 0.0040 0.0392
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsUROSEVIC_RESPONSE_TO_IMIQUIMOD http://www.broadinstitute.org/gsea/msigdb/cards/UROSEVIC_RESPONSE_TO_IMIQUIMOD 23 -0.7350 0.0010 0.0009
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSEMBA_FHIT_TARGETS_DN http://www.broadinstitute.org/gsea/msigdb/cards/SEMBA_FHIT_TARGETS_DN 10 -0.7344 0.0183 0.0239
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsBANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_UPhttp://www.broadinstitute.org/gsea/msigdb/cards/BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_UP9 -0.7342 0.0171 0.0218
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsGRANDVAUX_IFN_RESPONSE_NOT_VIA_IRF3 http://www.broadinstitute.org/gsea/msigdb/cards/GRANDVAUX_IFN_RESPONSE_NOT_VIA_IRF3 14 -0.7340 0.0034 0.0082
HGNCSigDB_dMay2014 gene families Chromatin-modifying enzymes Chromatin-modifying enzymes / K-demethylases http://www.genenames.org/genefamilies/KDM-KAT-KMT#KDM 20 -0.7338 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsMYLLYKANGAS_AMPLIFICATION_HOT_SPOT_12 http://www.broadinstitute.org/gsea/msigdb/cards/MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_1211 -0.7336 0.0085 0.0187
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsCASORELLI_APL_SECONDARY_VS_DE_NOVO_DNhttp://www.broadinstitute.org/gsea/msigdb/cards/CASORELLI_APL_SECONDARY_VS_DE_NOVO_DN9 -0.7335 0.0159 0.0245
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions CATION_TRANSPORTING_ATPASE_ACTIVITY http://www.broadinstitute.org/gsea/msigdb/cards/CATION_TRANSPORTING_ATPASE_ACTIVITY 11 -0.7333 0.0125 0.0407
GeneSigDB_v4_Sept2011 Human Breast Breast_Feng07_21genesUpRegulated http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=17123152-Table3b 20 -0.7315 0.0010 0.0073
GeneSigDB_v4_Sept2011 Human Lymphoma Lymphoma_Blenk08_16genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=18416826-Table2 11 -0.7299 0.0143 0.0187
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_402 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_402 12 -0.7293 0.0040 0.0047
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsBOWIE_RESPONSE_TO_TAMOXIFEN http://www.broadinstitute.org/gsea/msigdb/cards/BOWIE_RESPONSE_TO_TAMOXIFEN 18 -0.7271 0.0011 0.0050
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer gene neighborhoods GNF2_VAV1 http://www.broadinstitute.org/gsea/msigdb/cards/GNF2_VAV1 36 -0.7267 0.0010 0.0010
GeneSigDB_v4_Sept2011 Human StemCell StemCell_Roth05_11genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=15741219-Table2 9 -0.7266 0.0308 0.0253
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / KEGG KEGG_ASTHMA http://www.broadinstitute.org/gsea/msigdb/cards/KEGG_ASTHMA 30 -0.7264 0.0010 0.0009
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsGOLUB_ALL_VS_AML_UP http://www.broadinstitute.org/gsea/msigdb/cards/GOLUB_ALL_VS_AML_UP 24 -0.7261 0.0010 0.0009
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_G1_S_SPECIFIC_TRANSCRIPTION http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_G1_S_SPECIFIC_TRANSCRIPTION18 -0.7201 0.0030 0.0084
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions THYROID_HORMONE_RECEPTOR_BINDING http://www.broadinstitute.org/gsea/msigdb/cards/THYROID_HORMONE_RECEPTOR_BINDING 17 -0.7197 0.0012 0.0144
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components NUCLEAR_SPECK http://www.broadinstitute.org/gsea/msigdb/cards/NUCLEAR_SPECK 11 -0.7159 0.0138 0.0253
GeneSigDB_v4_Sept2011 Human Breast Breast_Sgroi99_16genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=10582678-Table1 11 -0.7149 0.0152 0.0174
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / KEGG KEGG_OTHER_GLYCAN_DEGRADATION http://www.broadinstitute.org/gsea/msigdb/cards/KEGG_OTHER_GLYCAN_DEGRADATION 16 -0.7145 0.0040 0.0015
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes ESTABLISHMENT_OF_ORGANELLE_LOCALIZATIONhttp://www.broadinstitute.org/gsea/msigdb/cards/ESTABLISHMENT_OF_ORGANELLE_LOCALIZATION18 -0.7100 0.0011 0.0207
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_BINDINGhttp://www.broadinstitute.org/gsea/msigdb/cards/INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_BINDING10 -0.7095 0.0252 0.0573
GeneSigDB_v4_Sept2011 Human Skin Skin_Zimmerer08_23genes_InVitrovsInVivo http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=18794103-Table3 20 -0.7046 0.0017 0.0070
StaudtSigDB_dNov2012 Transcription factor target NFkB NFkB_Up_OCILy3_only http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=87 10 -0.7041 0.0245 0.0152
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components VACUOLAR_MEMBRANE http://www.broadinstitute.org/gsea/msigdb/cards/VACUOLAR_MEMBRANE 11 -0.7034 0.0203 0.0246
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer gene neighborhoods GNF2_INPP5D http://www.broadinstitute.org/gsea/msigdb/cards/GNF2_INPP5D 43 -0.7032 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions BETA_TUBULIN_BINDING http://www.broadinstitute.org/gsea/msigdb/cards/BETA_TUBULIN_BINDING 10 -0.7019 0.0375 0.0477
Signature name Signature links Defined members
Enrichment 
score
P [GSEA]
(by permutation test)
COLLER_MYC_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/COLLER_MYC_TARGETS_UP 25 0.8405 0.0010
SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY http://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY 32 0.7853 0.0010
Myc_overexpression_1.5x_up http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=167 88 0.7573 0.0010
SCHUHMACHER_MYC_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/SCHUHMACHER_MYC_TARGETS_UP 80 0.7466 0.0010
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN http://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN 47 0.7138 0.0010
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP http://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 47 0.7127 0.0010
MENSSEN_MYC_TARGETS http://www.broadinstitute.org/gsea/msigdb/cards/MENSSEN_MYC_TARGETS 53 0.6902 0.0010
Myc_overexpression_2x_up http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=168 36 0.6781 0.0010
CAIRO_PML_TARGETS_BOUND_BY_MYC_DN http://www.broadinstitute.org/gsea/msigdb/cards/CAIRO_PML_TARGETS_BOUND_BY_MYC_DN 14 0.6580 0.0066
Supplemental Table 4. MYC signatures enriched with top regulated genes following z-VRPR-fmk treatment in Mino cells.
Downregulated signatures:
Supplemental Table 5. Downregulated and upregulated genes following z-VRPR-fmk treatment in Rec-1 cells.
Signature name Gene symbol Gene ID Gene description
Downregulated genes (alpha=0.0025)ANKRD27 84079 ankyrin repeat domain 27
Downregulated genes (alpha=0.0025)AQP3 360 aquaporin 3 (Gill blood group)
Downregulated genes (alpha=0.0025)ASH1L-AS1 645676 ASH1L antisense RNA 1
Downregulated genes (alpha=0.0025)ASS1 445 argininosuccinate synthase 1
Downregulated genes (alpha=0.0025)ASS1P11 340274 argininosuccinate synthetase 1 pseudogene 11
Downregulated genes (alpha=0.0025)ATP5C1 509 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1
Downregulated genes (alpha=0.0025)BCS1L 617 BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone
Downregulated genes (alpha=0.0025)C20orf27 54976 chromosome 20 open reading frame 27
Downregulated genes (alpha=0.0025)C9orf173 441476 sperm-tail PG-rich repeat containing 3
Downregulated genes (alpha=0.0025)CBX6 23466 chromobox 6
Downregulated genes (alpha=0.0025)CCNY 219771 cyclin Y
Downregulated genes (alpha=0.0025)CD3EAP 10849 CD3e molecule associated protein
Downregulated genes (alpha=0.0025)CHCHD4 131474 coiled-coil-helix-coiled-coil-helix domain containing 4
Downregulated genes (alpha=0.0025)CHEK2 11200 checkpoint kinase 2
Downregulated genes (alpha=0.0025)CIZ1 25792 CDKN1A interacting zinc finger protein 1
Downregulated genes (alpha=0.0025)CUX2 23316 cut like homeobox 2
Downregulated genes (alpha=0.0025)CXCR7 57007 atypical chemokine receptor 3
Downregulated genes (alpha=0.0025)CYSLTR1 10800 cysteinyl leukotriene receptor 1
Downregulated genes (alpha=0.0025)DANCR 57291 differentiation antagonizing non-protein coding RNA
Downregulated genes (alpha=0.0025)DEXI 28955 Dexi homolog
Downregulated genes (alpha=0.0025)ERCC8 1161 ERCC excision repair 8, CSA ubiquitin ligase complex subunit
Downregulated genes (alpha=0.0025)ERI3 79033 ERI1 exoribonuclease family member 3
Downregulated genes (alpha=0.0025)ETS2 2114 ETS proto-oncogene 2, transcription factor
Downregulated genes (alpha=0.0025)FAM203B 728071
Downregulated genes (alpha=0.0025)FAM81A 145773 family with sequence similarity 81 member A
Downregulated genes (alpha=0.0025)FDXACB1 91893 ferredoxin-fold anticodon binding domain containing 1
Downregulated genes (alpha=0.0025)FKBP4 2288 FK506 binding protein 4
Downregulated genes (alpha=0.0025)FLJ39739 388685 long intergenic non-protein coding RNA 1138
Downregulated genes (alpha=0.0025)GFM1 85476 G elongation factor mitochondrial 1
Downregulated genes (alpha=0.0025)GMDS 2762 GDP-mannose 4,6-dehydratase
Downregulated genes (alpha=0.0025)GRB14 2888 growth factor receptor bound protein 14
Downregulated genes (alpha=0.0025)HEY2 23493 hes related family bHLH transcription factor with YRPW motif 2
Downregulated genes (alpha=0.0025)HNRNPA1 3178 heterogeneous nuclear ribonucleoprotein A1
Downregulated genes (alpha=0.0025)IARS 3376 isoleucyl-tRNA synthetase
Downregulated genes (alpha=0.0025)IDH3A 3419 isocitrate dehydrogenase 3 (NAD(+)) alpha
Downregulated genes (alpha=0.0025)IL2RB 3560 interleukin 2 receptor subunit beta
Downregulated genes (alpha=0.0025)ITPK1 3705 inositol-tetrakisphosphate 1-kinase
Downregulated genes (alpha=0.0025)KLHL14 57565 kelch like family member 14
Downregulated genes (alpha=0.0025)KREMEN2 79412 kringle containing transmembrane protein 2
Downregulated genes (alpha=0.0025)LDHA 3939 lactate dehydrogenase A
Downregulated genes (alpha=0.0025)LFNG 3955 LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
Downregulated genes (alpha=0.0025)LMO3 55885 LIM domain only 3
Downregulated genes (alpha=0.0025)LOC146880 146880 Rho GTPase activating protein 27 pseudogene
Downregulated genes (alpha=0.0025)LOC642909 642909 C-terminal binding protein 2 pseudogene 4
Downregulated genes (alpha=0.0025)LOC644684 644684 BMS1, ribosome biogenesis factor pseudogene 12
Downregulated genes (alpha=0.0025)LOC653557 653557 BMS1, ribosome biogenesis factor pseudogene 8
Downregulated genes (alpha=0.0025)MARS2 92935 methionyl-tRNA synthetase 2, mitochondrial
Downregulated genes (alpha=0.0025)MESP1 55897 mesoderm posterior bHLH transcription factor 1
Downregulated genes (alpha=0.0025)MINA 84864 MYC induced nuclear antigen
Downregulated genes (alpha=0.0025)MRPS23 51649 mitochondrial ribosomal protein S23
Downregulated genes (alpha=0.0025)MSRB1 51734 methionine sulfoxide reductase B1
Downregulated genes (alpha=0.0025)MYCBP 26292 MYC binding protein
Downregulated genes (alpha=0.0025)NAA10 8260 N(alpha)-acetyltransferase 10, NatA catalytic subunit
Downregulated genes (alpha=0.0025)NCLN 56926 nicalin
Downregulated genes (alpha=0.0025)NDUFB8 4714 NADH:ubiquinone oxidoreductase subunit B8
Downregulated genes (alpha=0.0025)NOP16 51491 NOP16 nucleolar protein
Downregulated genes (alpha=0.0025)NPW 283869 neuropeptide W
Downregulated genes (alpha=0.0025)NT5DC3 51559 5'-nucleotidase domain containing 3
Downregulated genes (alpha=0.0025)NUFIP1 26747 NUFIP1, FMR1 interacting protein 1
Downregulated genes (alpha=0.0025)NUP35 129401 nucleoporin 35
Downregulated genes (alpha=0.0025)PDCL3 79031 phosducin like 3
Downregulated genes (alpha=0.0025)PDE7B 27115 phosphodiesterase 7B
Downregulated genes (alpha=0.0025)PDIA2 64714 protein disulfide isomerase family A member 2
Downregulated genes (alpha=0.0025)PDIA5 10954 protein disulfide isomerase family A member 5
Downregulated genes (alpha=0.0025)PHBP11 644214 prohibitin pseudogene 11
Downregulated genes (alpha=0.0025)PNPO 55163 pyridoxamine 5'-phosphate oxidase
Downregulated genes (alpha=0.0025)POLDIP2 26073 DNA polymerase delta interacting protein 2
Downregulated genes (alpha=0.0025)POLR1C 9533 RNA polymerase I subunit C
Downregulated genes (alpha=0.0025)POLR2F 5435 RNA polymerase II subunit F
Downregulated genes (alpha=0.0025)PPAN 56342 peter pan homolog (Drosophila)
Downregulated genes (alpha=0.0025)PSMG1 8624 proteasome assembly chaperone 1
Downregulated genes (alpha=0.0025)PTCD2 79810 pentatricopeptide repeat domain 2
Downregulated genes (alpha=0.0025)PTGES3P3 441050 prostaglandin E synthase 3 pseudogene 3
Downregulated genes (alpha=0.0025)RASA4 10156 RAS p21 protein activator 4
Downregulated genes (alpha=0.0025)RCBTB2 1102 RCC1 and BTB domain containing protein 2
Downregulated genes (alpha=0.0025)RDH10 157506 retinol dehydrogenase 10 (all-trans)
Downregulated genes (alpha=0.0025)RFESD 317671 Rieske Fe-S domain containing
Downregulated genes (alpha=0.0025)RPL26P30 653147 ribosomal protein L26 pseudogene 30
Downregulated genes (alpha=0.0025)RPL31P4 729646 ribosomal protein L31 pseudogene 4
Downregulated genes (alpha=0.0025)RPS7 6201 ribosomal protein S7
Downregulated genes (alpha=0.0025)RRP12 23223 ribosomal RNA processing 12 homolog
Downregulated genes (alpha=0.0025)RRP15 51018 ribosomal RNA processing 15 homolog
Downregulated genes (alpha=0.0025)RSAD1 55316 radical S-adenosyl methionine domain containing 1
Downregulated genes (alpha=0.0025)RUVBL1 8607 RuvB like AAA ATPase 1
Downregulated genes (alpha=0.0025)SART3 9733 squamous cell carcinoma antigen recognized by T-cells 3
Downregulated genes (alpha=0.0025)SBDSP1 155370 Shwachman-Bodian-Diamond syndrome pseudogene 1
Downregulated genes (alpha=0.0025)SCARNA13 677768 small Cajal body-specific RNA 13
Downregulated genes (alpha=0.0025)SDC3 9672 syndecan 3
Downregulated genes (alpha=0.0025)SLC16A9 220963 solute carrier family 16 member 9
Downregulated genes (alpha=0.0025)SLC19A1 6573 solute carrier family 19 member 1
Downregulated genes (alpha=0.0025)SLC25A19 60386 solute carrier family 25 member 19
Downregulated genes (alpha=0.0025)SLC25A39 51629 solute carrier family 25 member 39
Downregulated genes (alpha=0.0025)SNAPC4 6621 small nuclear RNA activating complex polypeptide 4
Downregulated genes (alpha=0.0025)SNORD96A 619571 small nucleolar RNA, C/D box 96A
Downregulated genes (alpha=0.0025)SPATA13 221178 spermatogenesis associated 13
Downregulated genes (alpha=0.0025)SREK1IP1 285672 SREK1 interacting protein 1
Downregulated genes (alpha=0.0025)STUB1 10273 STIP1 homology and U-box containing protein 1
Downregulated genes (alpha=0.0025)TAF4B 6875 TATA-box binding protein associated factor 4b
Downregulated genes (alpha=0.0025)TFRC 7037 transferrin receptor
Downregulated genes (alpha=0.0025)TIGIT 201633 T-cell immunoreceptor with Ig and ITIM domains
Downregulated genes (alpha=0.0025)TLE1P1 645381 transducin like enhancer of split 1 pseudogene 1
Downregulated genes (alpha=0.0025)TSFM 10102 Ts translation elongation factor, mitochondrial
Downregulated genes (alpha=0.0025)TUBA4A 7277 tubulin alpha 4a
Downregulated genes (alpha=0.0025)TUT1 64852 terminal uridylyl transferase 1, U6 snRNA-specific
Downregulated genes (alpha=0.0025)TYW3 127253 tRNA-yW synthesizing protein 3 homolog
Downregulated genes (alpha=0.0025)UNC93B3 285296 unc-93 homolog B3 pseudogene (C. elegans)
Downregulated genes (alpha=0.0025)UNC93B6 255620 unc-93 homolog B6 pseudogene (C. elegans)
Downregulated genes (alpha=0.0025)VMA21 203547 VMA21 vacuolar H+-ATPase homolog (S. cerevisiae)
Downregulated genes (alpha=0.0025)WDR4 10785 WD repeat domain 4
Downregulated genes (alpha=0.0025)YIF1A 10897 Yip1 interacting factor homolog A, membrane trafficking protein
Downregulated genes (alpha=0.0025)ZNF317 57693 zinc finger protein 317
Downregulated genes (alpha=0.0025)ZNF589 51385 zinc finger protein 589
Downregulated genes (alpha=0.0025)ZNRF3 84133 zinc and ring finger 3
Upregulated genes (alpha=0.0025) AACS 65985 acetoacetyl-CoA synthetase
Upregulated genes (alpha=0.0025) ABCA1 19 ATP binding cassette subfamily A member 1
Upregulated genes (alpha=0.0025) ABCG1 9619 ATP binding cassette subfamily G member 1
Upregulated genes (alpha=0.0025) ABI1 10006 abl interactor 1
Upregulated genes (alpha=0.0025) ACSF2 80221 acyl-CoA synthetase family member 2
Upregulated genes (alpha=0.0025) ACTA2 59 actin, alpha 2, smooth muscle, aorta
Upregulated genes (alpha=0.0025) ADA 100 adenosine deaminase
Upregulated genes (alpha=0.0025) ADARB1 104 adenosine deaminase, RNA specific B1
Upregulated genes (alpha=0.0025) ADSSL1 122622 adenylosuccinate synthase like 1
Upregulated genes (alpha=0.0025) AIM1 202 absent in melanoma 1
Upregulated genes (alpha=0.0025) AKAP8L 26993 A-kinase anchoring protein 8 like
Upregulated genes (alpha=0.0025) ALDH5A1 7915 aldehyde dehydrogenase 5 family member A1
Upregulated genes (alpha=0.0025) ALPK1 80216 alpha kinase 1
Upregulated genes (alpha=0.0025) AMY1B 277 amylase, alpha 1B (salivary)
Upregulated genes (alpha=0.0025) ANKRD12 23253 ankyrin repeat domain 12
Upregulated genes (alpha=0.0025) AP1G2 8906 adaptor related protein complex 1 gamma 2 subunit
Upregulated genes (alpha=0.0025) APOC2 344 apolipoprotein C2
Upregulated genes (alpha=0.0025) APOD 347 apolipoprotein D
Upregulated genes (alpha=0.0025) ARID5B 84159 AT-rich interaction domain 5B
Upregulated genes (alpha=0.0025) ARRB2 409 arrestin beta 2
Upregulated genes (alpha=0.0025) BAZ2B 29994 bromodomain adjacent to zinc finger domain 2B
Upregulated genes (alpha=0.0025) BCRP5 648980 breakpoint cluster region pseudogene 5
Upregulated genes (alpha=0.0025) BEST3 144453 bestrophin 3
Upregulated genes (alpha=0.0025) BHLHE40 8553 basic helix-loop-helix family member e40
Upregulated genes (alpha=0.0025) BIRC7 79444 baculoviral IAP repeat containing 7
Upregulated genes (alpha=0.0025) BRI3 25798 brain protein I3
Upregulated genes (alpha=0.0025) BRI3P1 730010 brain protein I3 pseudogene 1
Upregulated genes (alpha=0.0025) BTN2A2 10385 butyrophilin subfamily 2 member A2
Upregulated genes (alpha=0.0025) C12orf57 113246 chromosome 12 open reading frame 57
Upregulated genes (alpha=0.0025) C18orf8 29919 chromosome 18 open reading frame 8
Upregulated genes (alpha=0.0025) C1orf85 112770 glycosylated lysosomal membrane protein
Upregulated genes (alpha=0.0025) CAPN3 825 calpain 3
Upregulated genes (alpha=0.0025) CARHSP1 23589 calcium regulated heat stable protein 1
Upregulated genes (alpha=0.0025) CCDC109B 55013 mitochondrial calcium uniporter dominant negative beta subunit
Upregulated genes (alpha=0.0025) CCDC42B 387885 cilia and flagella associated protein 73
Upregulated genes (alpha=0.0025) CD52 1043 CD52 molecule
Upregulated genes (alpha=0.0025) CECR1 51816 cat eye syndrome chromosome region, candidate 1
Upregulated genes (alpha=0.0025) CIITA 4261 class II major histocompatibility complex transactivator
Upregulated genes (alpha=0.0025) CLEC9A 283420 C-type lectin domain family 9 member A
Upregulated genes (alpha=0.0025) CREBRF 153222 CREB3 regulatory factor
Upregulated genes (alpha=0.0025) CRIP1 1396 cysteine rich protein 1
Upregulated genes (alpha=0.0025) CXCL16 58191 C-X-C motif chemokine ligand 16
Upregulated genes (alpha=0.0025) DCAF5 8816 DDB1 and CUL4 associated factor 5
Upregulated genes (alpha=0.0025) DDAH2 23564 dimethylarginine dimethylaminohydrolase 2
Upregulated genes (alpha=0.0025) DDX54 79039 DEAD-box helicase 54
Upregulated genes (alpha=0.0025) DENND2D 79961 DENN domain containing 2D
Upregulated genes (alpha=0.0025) DFNA5 1687 DFNA5, deafness associated tumor suppressor
Upregulated genes (alpha=0.0025) DIP2C 22982 disco interacting protein 2 homolog C
Upregulated genes (alpha=0.0025) DPYSL2 1808 dihydropyrimidinase like 2
Upregulated genes (alpha=0.0025) DTX3L 151636 deltex E3 ubiquitin ligase 3L
Upregulated genes (alpha=0.0025) DYRK1B 9149 dual specificity tyrosine phosphorylation regulated kinase 1B
Upregulated genes (alpha=0.0025) EMP3 2014 epithelial membrane protein 3
Upregulated genes (alpha=0.0025) FAIM3 9214 Fc fragment of IgM receptor
Upregulated genes (alpha=0.0025) FAM60A 58516 family with sequence similarity 60 member A
Upregulated genes (alpha=0.0025) FBLN2 2199 fibulin 2
Upregulated genes (alpha=0.0025) FBXO15 201456 F-box protein 15
Upregulated genes (alpha=0.0025) FBXO32 114907 F-box protein 32
Upregulated genes (alpha=0.0025) FCGRT 2217 Fc fragment of IgG receptor and transporter
Upregulated genes (alpha=0.0025) FLJ42627 645644 uncharacterized LOC645644
Upregulated genes (alpha=0.0025) FOXN3 1112 forkhead box N3
Upregulated genes (alpha=0.0025) GABARAPL2 11345 GABA type A receptor associated protein like 2
Upregulated genes (alpha=0.0025) GATS 352954 GATS, stromal antigen 3 opposite strand
Upregulated genes (alpha=0.0025) GFI1 2672 growth factor independent 1 transcriptional repressor
Upregulated genes (alpha=0.0025) GIMAP8 155038 GTPase, IMAP family member 8
Upregulated genes (alpha=0.0025) GLRX 2745 glutaredoxin
Upregulated genes (alpha=0.0025) GM2A 2760 GM2 ganglioside activator
Upregulated genes (alpha=0.0025) GNG7 2788 G protein subunit gamma 7
Upregulated genes (alpha=0.0025) GPR137C 283554 G protein-coupled receptor 137C
Upregulated genes (alpha=0.0025) GPR160 26996 G protein-coupled receptor 160
Upregulated genes (alpha=0.0025) GYPC 2995 glycophorin C (Gerbich blood group)
Upregulated genes (alpha=0.0025) H1FX 8971 H1 histone family member X
Upregulated genes (alpha=0.0025) HAVCR2 84868 hepatitis A virus cellular receptor 2
Upregulated genes (alpha=0.0025) HBA2 3040 hemoglobin subunit alpha 2
Upregulated genes (alpha=0.0025) HCP5 10866 HLA complex P5 (non-protein coding)
Upregulated genes (alpha=0.0025) HELQ 113510 helicase, POLQ-like
Upregulated genes (alpha=0.0025) HILPDA 29923 hypoxia inducible lipid droplet associated
Upregulated genes (alpha=0.0025) HIP1 3092 huntingtin interacting protein 1
Upregulated genes (alpha=0.0025) HLA-DMA 3108 major histocompatibility complex, class II, DM alpha
Upregulated genes (alpha=0.0025) HLA-DMB 3109 major histocompatibility complex, class II, DM beta
Upregulated genes (alpha=0.0025) HLA-DOA 3111 major histocompatibility complex, class II, DO alpha
Upregulated genes (alpha=0.0025) HLA-DOB 3112 major histocompatibility complex, class II, DO beta
Upregulated genes (alpha=0.0025) HLA-DPB1 3115 major histocompatibility complex, class II, DP beta 1
Upregulated genes (alpha=0.0025) HLA-DQA1 3117 major histocompatibility complex, class II, DQ alpha 1
Upregulated genes (alpha=0.0025) HLA-DRA 3122 major histocompatibility complex, class II, DR alpha
Upregulated genes (alpha=0.0025) HLA-DRB1 3123 major histocompatibility complex, class II, DR beta 1
Upregulated genes (alpha=0.0025) HLA-DRB3 3125 major histocompatibility complex, class II, DR beta 3
Upregulated genes (alpha=0.0025) HLA-DRB4 3126 major histocompatibility complex, class II, DR beta 4
Upregulated genes (alpha=0.0025) HLA-E 3133 major histocompatibility complex, class I, E
Upregulated genes (alpha=0.0025) HSPB1P1 653553 heat shock protein family B (small) member 1 pseudogene 1
Upregulated genes (alpha=0.0025) IFIH1 64135 interferon induced with helicase C domain 1
Upregulated genes (alpha=0.0025) IFIT2 3433 interferon induced protein with tetratricopeptide repeats 2
Upregulated genes (alpha=0.0025) IL10RB 3588 interleukin 10 receptor subunit beta
Upregulated genes (alpha=0.0025) IL4R 3566 interleukin 4 receptor
Upregulated genes (alpha=0.0025) IRF1 3659 interferon regulatory factor 1
Upregulated genes (alpha=0.0025) IRF2BPL 64207 interferon regulatory factor 2 binding protein like
Upregulated genes (alpha=0.0025) IRS2 8660 insulin receptor substrate 2
Upregulated genes (alpha=0.0025) KANSL1L 151050 KAT8 regulatory NSL complex subunit 1 like
Upregulated genes (alpha=0.0025) KLF2 10365 Kruppel like factor 2
Upregulated genes (alpha=0.0025) KLHDC8B 200942 kelch domain containing 8B
Upregulated genes (alpha=0.0025) KLHL22 84861 kelch like family member 22
Upregulated genes (alpha=0.0025) KLHL24 54800 kelch like family member 24
Upregulated genes (alpha=0.0025) KLHL6 89857 kelch like family member 6
Upregulated genes (alpha=0.0025) LGALS1 3956 galectin 1
Upregulated genes (alpha=0.0025) LILRB4 11006 leukocyte immunoglobulin like receptor B4
Upregulated genes (alpha=0.0025) LINC00426 100188949 long intergenic non-protein coding RNA 426
Upregulated genes (alpha=0.0025) LITAF 9516 lipopolysaccharide induced TNF factor
Upregulated genes (alpha=0.0025) LMOD3 56203 leiomodin 3
Upregulated genes (alpha=0.0025) LOC100129550100129550 uncharacterized LOC100129550
Upregulated genes (alpha=0.0025) LOC100130276100130276 uncharacterized LOC100130276
Upregulated genes (alpha=0.0025) LOC440864 440864 uncharacterized LOC440864
Upregulated genes (alpha=0.0025) LOC644173 644173 uncharacterized LOC644173
Upregulated genes (alpha=0.0025) LOC644634 644634 family with sequence similarity 231 member D
Upregulated genes (alpha=0.0025) LOC728743 728743 zinc finger protein pseudogene
Upregulated genes (alpha=0.0025) LPIN1 23175 lipin 1
Upregulated genes (alpha=0.0025) LRMP 4033 lymphoid restricted membrane protein
Upregulated genes (alpha=0.0025) LY9 4063 lymphocyte antigen 9
Upregulated genes (alpha=0.0025) LY96 23643 lymphocyte antigen 96
Upregulated genes (alpha=0.0025) MACF1 23499 microtubule-actin crosslinking factor 1
Upregulated genes (alpha=0.0025) MDK 4192 midkine (neurite growth-promoting factor 2)
Upregulated genes (alpha=0.0025) MEF2D 4209 myocyte enhancer factor 2D
Upregulated genes (alpha=0.0025) MFGE8 4240 milk fat globule-EGF factor 8 protein
Upregulated genes (alpha=0.0025) MGC72080 389538 MGC72080 pseudogene
Upregulated genes (alpha=0.0025) MICAL1 64780 microtubule associated monooxygenase, calponin and LIM domain containing 1
Upregulated genes (alpha=0.0025) MIS18BP1 55320 MIS18 binding protein 1
Upregulated genes (alpha=0.0025) MMP11 4320 matrix metallopeptidase 11
Upregulated genes (alpha=0.0025) MVP 9961 major vault protein
Upregulated genes (alpha=0.0025) MXD3 83463 MAX dimerization protein 3
Upregulated genes (alpha=0.0025) MYB 4602 MYB proto-oncogene, transcription factor
Upregulated genes (alpha=0.0025) MYO1G 64005 myosin IG
Upregulated genes (alpha=0.0025) NEU1 4758 neuraminidase 1
Upregulated genes (alpha=0.0025) NFATC2IP 84901 nuclear factor of activated T-cells 2 interacting protein
Upregulated genes (alpha=0.0025) NPC2 10577 NPC intracellular cholesterol transporter 2
Upregulated genes (alpha=0.0025) NPIPL3 23117 nuclear pore complex interacting protein family member B3
Upregulated genes (alpha=0.0025) NREP 9315 neuronal regeneration related protein
Upregulated genes (alpha=0.0025) NUAK2 81788 NUAK family kinase 2
Upregulated genes (alpha=0.0025) NUCB2 4925 nucleobindin 2
Upregulated genes (alpha=0.0025) OAS1 4938 2'-5'-oligoadenylate synthetase 1
Upregulated genes (alpha=0.0025) OAS2 4939 2'-5'-oligoadenylate synthetase 2
Upregulated genes (alpha=0.0025) OAS3 4940 2'-5'-oligoadenylate synthetase 3
Upregulated genes (alpha=0.0025) P2RX4 5025 purinergic receptor P2X 4
Upregulated genes (alpha=0.0025) P2RY8 286530 purinergic receptor P2Y8
Upregulated genes (alpha=0.0025) PARP15 165631 poly(ADP-ribose) polymerase family member 15
Upregulated genes (alpha=0.0025) PARP9 83666 poly(ADP-ribose) polymerase family member 9
Upregulated genes (alpha=0.0025) PARVG 64098 parvin gamma
Upregulated genes (alpha=0.0025) PATL2 197135 PAT1 homolog 2
Upregulated genes (alpha=0.0025) PCNX 22990 pecanex homolog 1 (Drosophila)
Upregulated genes (alpha=0.0025) PHEX 5251 phosphate regulating endopeptidase homolog, X-linked
Upregulated genes (alpha=0.0025) PIK3C2B 5287 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta
Upregulated genes (alpha=0.0025) PIK3IP1 113791 phosphoinositide-3-kinase interacting protein 1
Upregulated genes (alpha=0.0025) PINK1 65018 PTEN induced putative kinase 1
Upregulated genes (alpha=0.0025) PLA2G2C 391013 phospholipase A2 group IIC
Upregulated genes (alpha=0.0025) PLAU 5328 plasminogen activator, urokinase
Upregulated genes (alpha=0.0025) PLXNB1 5364 plexin B1
Upregulated genes (alpha=0.0025) PPP1R15A 23645 protein phosphatase 1 regulatory subunit 15A
Upregulated genes (alpha=0.0025) PRR5 55615 proline rich 5
Upregulated genes (alpha=0.0025) PYCARD 29108 PYD and CARD domain containing
Upregulated genes (alpha=0.0025) PYROXD2 84795 pyridine nucleotide-disulphide oxidoreductase domain 2
Upregulated genes (alpha=0.0025) RAB11FIP1 80223 RAB11 family interacting protein 1
Upregulated genes (alpha=0.0025) RAB37 326624 RAB37, member RAS oncogene family
Upregulated genes (alpha=0.0025) RARRES2 5919 retinoic acid receptor responder 2
Upregulated genes (alpha=0.0025) RENBP 5973 renin binding protein
Upregulated genes (alpha=0.0025) RHBDF1 64285 rhomboid 5 homolog 1
Upregulated genes (alpha=0.0025) RHOBTB2 23221 Rho related BTB domain containing 2
Upregulated genes (alpha=0.0025) RHOQ 23433 ras homolog family member Q
Upregulated genes (alpha=0.0025) RNF144A 9781 ring finger protein 144A
Upregulated genes (alpha=0.0025) RNF44 22838 ring finger protein 44
Upregulated genes (alpha=0.0025) RRAGD 58528 Ras related GTP binding D
Upregulated genes (alpha=0.0025) RRN3P2 653390 RRN3 homolog, RNA polymerase I transcription factor pseudogene 2
Upregulated genes (alpha=0.0025) S1PR4 8698 sphingosine-1-phosphate receptor 4
Upregulated genes (alpha=0.0025) SAMD9 54809 sterile alpha motif domain containing 9
Upregulated genes (alpha=0.0025) SAMD9L 219285 sterile alpha motif domain containing 9 like
Upregulated genes (alpha=0.0025) SBK1 388228 SH3 domain binding kinase 1
Upregulated genes (alpha=0.0025) SERPINB9 5272 serpin family B member 9
Upregulated genes (alpha=0.0025) SGSH 6448 N-sulfoglucosamine sulfohydrolase
Upregulated genes (alpha=0.0025) SLC15A4 121260 solute carrier family 15 member 4
Upregulated genes (alpha=0.0025) SLC26A11 284129 solute carrier family 26 member 11
Upregulated genes (alpha=0.0025) SLC29A4 222962 solute carrier family 29 member 4
Upregulated genes (alpha=0.0025) SLC29A4P1 402509 solute carrier family 29 member 4 pseudogene 1
Upregulated genes (alpha=0.0025) SMG1 23049 SMG1, nonsense mediated mRNA decay associated PI3K related kinase
Upregulated genes (alpha=0.0025) SNORA72 26775 small nucleolar RNA, H/ACA box 72
Upregulated genes (alpha=0.0025) SNX30 401548 sorting nexin family member 30
Upregulated genes (alpha=0.0025) SOX11 6664 SRY-box 11
Upregulated genes (alpha=0.0025) SOX8 30812 SRY-box 8
Upregulated genes (alpha=0.0025) SSBP2 23635 single stranded DNA binding protein 2
Upregulated genes (alpha=0.0025) ST3GAL5 8869 ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Upregulated genes (alpha=0.0025) STAT2 6773 signal transducer and activator of transcription 2
Upregulated genes (alpha=0.0025) SUN2 25777 Sad1 and UNC84 domain containing 2
Upregulated genes (alpha=0.0025) SYS1 90196 SYS1, golgi trafficking protein
Upregulated genes (alpha=0.0025) TCL1B 9623 T-cell leukemia/lymphoma 1B
Upregulated genes (alpha=0.0025) TIAF1 9220 TGFB1-induced anti-apoptotic factor 1
Upregulated genes (alpha=0.0025) TM2D1 83941 TM2 domain containing 1
Upregulated genes (alpha=0.0025) TMEM91 641649 transmembrane protein 91
Upregulated genes (alpha=0.0025) TMX4 56255 thioredoxin related transmembrane protein 4
Upregulated genes (alpha=0.0025) TNFRSF14 8764 TNF receptor superfamily member 14
Upregulated genes (alpha=0.0025) TNFRSF17 608 TNF receptor superfamily member 17
Upregulated genes (alpha=0.0025) TOP2B 7155 topoisomerase (DNA) II beta
Upregulated genes (alpha=0.0025) TOX2 84969 TOX high mobility group box family member 2
Upregulated genes (alpha=0.0025) TP53INP1 94241 tumor protein p53 inducible nuclear protein 1
Upregulated genes (alpha=0.0025) TPP1 1200 tripeptidyl peptidase 1
Upregulated genes (alpha=0.0025) TRIB1 10221 tribbles pseudokinase 1
Upregulated genes (alpha=0.0025) TRIM13 10206 tripartite motif containing 13
Upregulated genes (alpha=0.0025) TRIM22 10346 tripartite motif containing 22
Upregulated genes (alpha=0.0025) TSC22D1 8848 TSC22 domain family member 1
Upregulated genes (alpha=0.0025) TSC22D3 1831 TSC22 domain family member 3
Upregulated genes (alpha=0.0025) TSPAN32 10077 tetraspanin 32
Upregulated genes (alpha=0.0025) TUG1 55000 taurine up-regulated 1 (non-protein coding)
Upregulated genes (alpha=0.0025) TYROBP 7305 TYRO protein tyrosine kinase binding protein
Upregulated genes (alpha=0.0025) UAP1L1 91373 UDP-N-acetylglucosamine pyrophosphorylase 1 like 1
Upregulated genes (alpha=0.0025) UBE2L6 9246 ubiquitin conjugating enzyme E2 L6
Upregulated genes (alpha=0.0025) VANGL2 57216 VANGL planar cell polarity protein 2
Upregulated genes (alpha=0.0025) WIPI2 26100 WD repeat domain, phosphoinositide interacting 2
Upregulated genes (alpha=0.0025) WNT3 7473 Wnt family member 3
Upregulated genes (alpha=0.0025) YPEL1 29799 yippee like 1
Upregulated genes (alpha=0.0025) YPEL2 388403 yippee like 2
Upregulated genes (alpha=0.0025) YPEL3 83719 yippee like 3
Upregulated genes (alpha=0.0025) YPEL5 51646 yippee like 5
Upregulated genes (alpha=0.0025) ZC3H12B 340554 zinc finger CCCH-type containing 12B
Upregulated genes (alpha=0.0025) ZHX2 22882 zinc fingers and homeoboxes 2
Upregulated genes (alpha=0.0025) ZNF219 51222 zinc finger protein 219
Upregulated genes (alpha=0.0025) ZNF260 339324 zinc finger protein 260
Upregulated genes (alpha=0.0025) ZNF608 57507 zinc finger protein 608
Upregulated genes (alpha=0.0025) ZSCAN16 80345 zinc finger and SCAN domain containing 16
Upregulated genes (alpha=0.0025) ZSCAN2 54993 zinc finger and SCAN domain containing 2
Signatures DB Category Sub Category Signature name Signature links
Defined 
members Enrichment score
P [GSEA]
(by permutation test) FDR [GSEA] 
HGNCSigDB_dMay2014 gene families Mitochondrial respiratory chain complexMitochondrial respiratory chain complex / Complex III http://www.genenames.org/genefamilies/mitocomplex#comIII 9 0.8030 0.0036 0.0064
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes RESPONSE_TO_HEAT http://www.broadinstitute.org/gsea/msigdb/cards/RESPONSE_TO_HEAT 10 0.8013 0.0051 0.0202
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes DNA_FRAGMENTATION_DURING_APOPTOSIS http://www.broadinstitute.org/gsea/msigdb/cards/DNA_FRAGMENTATION_DURING_APOPTOSIS 13 0.7959 0.0010 0.0146
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsCOLLER_MYC_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/COLLER_MYC_TARGETS_UP 25 0.7935 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / KEGG KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIShttp://www.broadinstitute.org/gsea/msigdb/cards/KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIS11 0.7877 0.0018 0.0019
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsMULLIGAN_NTF3_SIGNALING_VIA_INSR_AND_IGF1R_UPhttp://www.broadinstitute.org/gsea/msigdb/cards/MULLIGAN_NTF3_SIGNALING_VIA_INSR_AND_IGF1R_UP23 0.7860 0.0010 0.0010
GeneSigDB_v4_Sept2011 Human Viral Viral_Tsunedomi06_12genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=17088983-Table2a 12 0.7793 0.0016 0.0084
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_50 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_50 13 0.7783 0.0010 0.0107
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_514 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_514 10 0.7761 0.0019 0.0125
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_RNA_POL_III_CHAIN_ELONGATION http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_RNA_POL_III_CHAIN_ELONGATION17 0.7758 0.0010 0.0017
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsMYLLYKANGAS_AMPLIFICATION_HOT_SPOT_29 http://www.broadinstitute.org/gsea/msigdb/cards/MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_298 0.7744 0.0049 0.0134
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHUHMACHER_MYC_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/SCHUHMACHER_MYC_TARGETS_UP 80 0.7722 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components ORGANELLAR_SMALL_RIBOSOMAL_SUBUNIT http://www.broadinstitute.org/gsea/msigdb/cards/ORGANELLAR_SMALL_RIBOSOMAL_SUBUNIT 11 0.7618 0.0040 0.0029
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components MITOCHONDRIAL_SMALL_RIBOSOMAL_SUBUNIT http://www.broadinstitute.org/gsea/msigdb/cards/MITOCHONDRIAL_SMALL_RIBOSOMAL_SUBUNIT11 0.7618 0.0040 0.0029
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components SMALL_RIBOSOMAL_SUBUNIT http://www.broadinstitute.org/gsea/msigdb/cards/SMALL_RIBOSOMAL_SUBUNIT 11 0.7618 0.0040 0.0029
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DNhttp://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN47 0.7549 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsXU_RESPONSE_TO_TRETINOIN_AND_NSC682994_DNhttp://www.broadinstitute.org/gsea/msigdb/cards/XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_DN15 0.7505 0.0010 0.0016
GeneSigDB_v4_Sept2011 Mouse StemCell homolog(StemCell_Parker05_27genes, from Mus musculus, to Homo sapiens, 15 of 15 genes)http://www.genesigdb.org/genesi db/signaturedetail.jsp?signatureId=15992799-table2 15 0.7483 0.0020 0.0088
StaudtSigDB_dNov2012 Signaling pathway T cell cytokine signallng Tcell_cytokine_induced_prolif http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=77 27 0.7472 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsFU_INTERACT_WITH_ALKBH8 http://www.broadinstitute.org/gsea/msigdb/cards/FU_INTERACT_WITH_ALKBH8 13 0.7457 0.0040 0.0048
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsFUNG_IL2_SIGNALING_1 http://www.broadinstitute.org/gsea/msigdb/cards/FUNG_IL2_SIGNALING_1 11 0.7446 0.0051 0.0076
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes PROTEIN_TARGETING_TO_MITOCHONDRION http://www.broadinstitute.org/gsea/msigdb/cards/PROTEIN_TARGETING_TO_MITOCHONDRION 11 0.7437 0.0017 0.0342
HGNCSigDB_dMay2014 gene families Mitochondrial ribosomal proteins Mitochondrial ribosomal proteins / large subunits http://www.genenames.org/genefamilies/MRP#MRPL 49 0.7426 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes RRNA_METABOLIC_PROCESS http://www.broadinstitute.org/gsea/msigdb/cards/RRNA_METABOLIC_PROCESS 16 0.7409 0.0010 0.0064
StaudtSigDB_dNov2012 Signaling pathway Notch Notch_T-ALL_up_Palomero http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=235 47 0.7353 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UPhttp://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP47 0.7346 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / KEGG KEGG_CITRATE_CYCLE_TCA_CYCLE http://www.broadinstitute.org/gsea/msigdb/cards/KEGG_CITRATE_CYCLE_TCA_CYCLE 32 0.7341 0.0010 0.0010
HGNCSigDB_dMay2014 gene families RNA polymerase subunits RNA polymerase subunits http://www.genenames.org/genefamilies/POLR 29 0.7336 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components RIBOSOMAL_SUBUNIT http://www.broadinstitute.org/gsea/msigdb/cards/RIBOSOMAL_SUBUNIT 20 0.7331 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_RNA_POL_III_TRANSCRIPTION_TERMINATIONhttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_RNA_POL_III_TRANSCRIPTION_TERMINATION19 0.7313 0.0010 0.0017
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes RRNA_PROCESSING http://www.broadinstitute.org/gsea/msigdb/cards/RRNA_PROCESSING 15 0.7307 0.0010 0.0138
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes CELLULAR_RESPONSE_TO_STIMULUS http://www.broadinstitute.org/gsea/msigdb/cards/CELLULAR_RESPONSE_TO_STIMULUS 19 0.7304 0.0010 0.0096
StaudtSigDB_dNov2012 Signaling pathway MYC Myc_overexpression_1.5x_up http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=167 86 0.7271 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsRAHMAN_TP53_TARGETS_PHOSPHORYLATED http://www.broadinstitute.org/gsea/msigdb/cards/RAHMAN_TP53_TARGETS_PHOSPHORYLATED21 0.7218 0.0010 0.0010
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_25 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_25 13 0.7214 0.0059 0.0157
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_PURINE_RIBONUCLEOSIDE_MONOPHOSPHATE_BIOSYNTHESIShttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_PURINE_RIBONUCLEOSIDE_MONOPHOSPHATE_BIOSYNTHESIS11 0.7173 0.0182 0.0128
StaudtSigDB_dNov2012 Signaling pathway IL6 IL6_Ly10_Up_group2 http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=255 9 0.7166 0.0416 0.0083
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components ORGANELLAR_RIBOSOME http://www.broadinstitute.org/gsea/msigdb/cards/ORGANELLAR_RIBOSOME 22 0.7160 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components MITOCHONDRIAL_RIBOSOME http://www.broadinstitute.org/gsea/msigdb/cards/MITOCHONDRIAL_RIBOSOME 22 0.7160 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_VITAMIN_B5_PANTOTHENATE_METABOLISMhttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_VITAMIN_B5_PANTOTHENATE_METABOLISM11 0.7156 0.0141 0.0139
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer gene neighborhoods GNF2_MSH6 http://www.broadinstitute.org/gsea/msigdb/cards/GNF2_MSH6 31 0.7125 0.0010 0.0010
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components NUCLEOLAR_PART http://www.broadinstitute.org/gsea/msigdb/cards/NUCLEOLAR_PART 18 0.7103 0.0010 0.0019
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions NEUTRAL_AMINO_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITYhttp://www.broadinstitute.org/gsea/msigdb/cards/NEUTRAL_AMINO_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY12 0.7098 0.0197 0.0445
GeneSigDB_v4_Sept2011 Mouse Bone homolog(Bone_Kalajzic05_12genes, from Mus musculus, to Homo sapiens, 10 of 11 genes)http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=15834136-Table3 10 0.7085 0.0232 0.0533
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes COFACTOR_TRANSPORT http://www.broadinstitute.org/gsea/msigdb/cards/COFACTOR_TRANSPORT 11 0.7071 0.0126 0.0709
HGNCSigDB_dMay2014 gene families Mitochondrial respiratory chain complexMitochondrial respiratory chain complex / Complex V http://www.genenames.org/genefamilies/mitocomplex#FATP 16 0.7046 0.0062 0.0057
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes RNA_3END_PROCESSING http://www.broadinstitute.org/gsea/msigdb/cards/RNA_3END_PROCESSING 10 0.7036 0.0225 0.0767
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer gene neighborhoods MORF_GSPT1 http://www.broadinstitute.org/gsea/msigdb/cards/MORF_GSPT1 49 0.7007 0.0010 0.0010
Signatures DB Category Sub Category Signature name Signature links
Defined 
members Enrichment score
P [GSEA]
(by permutation test) FDR [GSEA] 
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_293 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_293 12 -0.8649 0.0010 0.0010
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_143 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_143 14 -0.8577 0.0010 0.0010
HGNCSigDB_dMay2014 gene families Histocompatibility complex Histocompatibility complex http://www.genenames.org/genefamilies/HLA 24 -0.8512 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsBOWIE_RESPONSE_TO_TAMOXIFEN http://www.broadinstitute.org/gsea/msigdb/cards/BOWIE_RESPONSE_TO_TAMOXIFEN 18 -0.8231 0.0010 0.0009
GeneSigDB_v4_Sept2011 Human Stomach Stomach_Nakamura09_9genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=19881313-Table1c 9 -0.8083 0.0010 0.0154
GeneSigDB_v4_Sept2011 Human Colon Colon_Protiva09_31genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=19139017-Table3 23 -0.7961 0.0010 0.0010
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_CASPASE_MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINShttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_CASPASE_MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINS12 -0.7938 0.0010 0.0302
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsUROSEVIC_RESPONSE_TO_IMIQUIMOD http://www.broadinstitute.org/gsea/msigdb/cards/UROSEVIC_RESPONSE_TO_IMIQUIMOD 23 -0.7827 0.0010 0.0009
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsCASORELLI_APL_SECONDARY_VS_DE_NOVO_DNhttp://www.broadinstitute.org/gsea/msigdb/cards/CASORELLI_APL_SECONDARY_VS_DE_NOVO_DN9 -0.7816 0.0097 0.0198
GeneSigDB_v4_Sept2011 Human StemCell StemCell_Roth05_11genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=15741219-Table2 9 -0.7733 0.0089 0.0263
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsCHASSOT_SKIN_WOUND http://www.broadinstitute.org/gsea/msigdb/cards/CHASSOT_SKIN_WOUND 10 -0.7687 0.0098 0.0174
MolSigDBv4_0_dMay2014 c4: computational gene sets cancer modules MODULE_543 http://www.broadinstitute.org/gsea/msigdb/cards/MODULE_543 17 -0.7683 0.0010 0.0010
GeneSigDB_v4_Sept2011 Human Leukemia Leukemia_Wilson06_15genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=16597596-TableS6-2 14 -0.7669 0.0010 0.0081
HGNCSigDB_dMay2014 gene families Metallothioneins Metallothioneins http://www.genenames.org/genefamilies/MT 18 -0.7653 0.0010 0.0010
StaudtSigDB_dNov2012 Transcription factor target NFkB NFkB_Up_OCILy3_only http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=87 10 -0.7627 0.0124 0.0035
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsZHANG_INTERFERON_RESPONSE http://www.broadinstitute.org/gsea/msigdb/cards/ZHANG_INTERFERON_RESPONSE 23 -0.7589 0.0010 0.0009
StaudtSigDB_dNov2012 Transcription factor target NFkB NFkB_ChIPCHIP_Young_5factors http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=271 15 -0.7519 0.0015 0.0023
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets biological processes GLYCOPROTEIN_CATABOLIC_PROCESS http://www.broadinstitute.org/gsea/msigdb/cards/GLYCOPROTEIN_CATABOLIC_PROCESS 12 -0.7515 0.0018 0.1156
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY8 -0.7510 0.0342 0.0761
GeneSigDB_v4_Sept2011 Human Kidney Kidney_Struckmann04_13genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=14996721-Table1b 13 -0.7491 0.0016 0.0178
Downregulated signatures:
Supplemental Table 6. Signatures that are significantly enriched with top regulated genes following z-VRPR-fmk treatment in Rec-1 cells.
Upregulated signatures:
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsMOSERLE_IFNA_RESPONSE http://www.broadinstitute.org/gsea/msigdb/cards/MOSERLE_IFNA_RESPONSE 31 -0.7402 0.0010 0.0009
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets molecular functions SIALYLTRANSFERASE_ACTIVITY http://www.broadinstitute.org/gsea/msigdb/cards/SIALYLTRANSFERASE_ACTIVITY 10 -0.7367 0.0133 0.1538
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsIIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_UPhttp://www.broadinstitute.org/gsea/msigdb/cards/IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_UP12 -0.7334 0.0032 0.0161
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsSCHMAHL_PDGF_SIGNALING http://www.broadinstitute.org/gsea/msigdb/cards/SCHMAHL_PDGF_SIGNALING 9 -0.7323 0.0456 0.0358
GeneSigDB_v4_Sept2011 Human Liver Liver_Liu03_11genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=14728809-Table3b 9 -0.7310 0.0324 0.0338
GeneSigDB_v4_Sept2011 Human Lung Lung_Magda08_21genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=18593933-Table1a 14 -0.7297 0.0049 0.0196
GeneSigDB_v4_Sept2011 Human Lymphoma Lymphoma_Fogel07_33genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=17092989-SuppTable1 29 -0.7289 0.0010 0.0010
GeneSigDB_v4_Sept2011 Human Lung Lung_Nam10_10genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=20369051-Table1 9 -0.7288 0.0212 0.0329
GeneSigDB_v4_Sept2011 Human Thyroid Thyroid_Amin09_10genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=19047894-Table2a 10 -0.7285 0.0214 0.0309
GeneSigDB_v4_Sept2011 Human Skin Skin_Zimmerer08_23genes_InVitrovsInVivo http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=18794103-Table3 20 -0.7278 0.0010 0.0045
GeneSigDB_v4_Sept2011 Human Prostate Prostate_Rothermund05_15genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=15790403-Table1 11 -0.7271 0.0078 0.0278
MolSigDBv4_0_dMay2014 c2: curated gene sets canonical pathways / Reactome REACTOME_DIGESTION_OF_DIETARY_CARBOHYDRATEhttp://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_DIGESTION_OF_DIETARY_CARBOHYDRATE9 -0.7187 0.0594 0.1042
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsBOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIXhttp://www.broadinstitute.org/gsea/msigdb/cards/BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX17 -0.7178 0.0029 0.0071
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsZHENG_RESPONSE_TO_ARSENITE_UP http://www.broadinstitute.org/gsea/msigdb/cards/ZHENG_RESPONSE_TO_ARSENITE_UP 18 -0.7172 0.0010 0.0060
StaudtSigDB_dNov2012 Signaling pathway Notch Notch_T-ALL_down_Sharma http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=229 18 -0.7156 0.0020 0.0027
GeneSigDB_v4_Sept2011 Human Viral Viral_Guo05_21genes http://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=16254373-Table3 18 -0.7141 0.0010 0.0085
StaudtSigDB_dNov2012 Signaling pathway Notch Notch_T-ALL_down_Palomero http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=236 14 -0.7124 0.0050 0.0026
MolSigDBv4_0_dMay2014 c2: curated gene sets chemical and genetic perturbationsBOYAULT_LIVER_CANCER_SUBCLASS_G5_DN http://www.broadinstitute.org/gsea/msigdb/cards/BOYAULT_LIVER_CANCER_SUBCLASS_G5_DN27 -0.7099 0.0010 0.0009
GeneSigDB_v4_Sept2011 Human Leukemia Leukemia_Ueno09_30genes_HighestUpRegulation3Dayshttp://www.genesigdb.org/genesigdb/signaturedetail.jsp?signatureId=19749795-SuppTable1 22 -0.7081 0.0010 0.0058
StaudtSigDB_dNov2012 Cancer differential Diffuse large B cell lymphoma PMBLhigh_HLlow http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=6 8 -0.7072 0.0625 0.0156
MolSigDBv4_0_dMay2014 c5: gene ontology (GO) gene sets cellular components ENDOCYTIC_VESICLE http://www.broadinstitute.org/gsea/msigdb/cards/ENDOCYTIC_VESICLE 14 -0.7032 0.0098 0.0518
Signature name Signature links Defined members
Enrichment 
score
P [GSEA]
(by permutation test)
COLLER_MYC_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/COLLER_MYC_TARGETS_UP 25 0.7935 0.0010
SCHUHMACHER_MYC_TARGETS_UP http://www.broadinstitute.org/gsea/msigdb/cards/SCHUHMACHER_MYC_TARGETS_UP 80 0.7722 0.0010
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN http://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN 47 0.7549 0.0010
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP http://www.broadinstitute.org/gsea/msigdb/cards/SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 47 0.7346 0.0010
Myc_overexpression_1.5x_up http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=167 86 0.7271 0.0010
Myc_overexpression_2x_up http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_DisplayGenes.cgi?signatureID=168 34 0.6827 0.0010
Supplemental Table 7. MYC signatures enriched with top regulated genes following z-VRPR-fmk treatment in Rec-1 cells.
Downregulated signatures:
